diff --git "a/test_predictions.txt" "b/test_predictions.txt"
new file mode 100644--- /dev/null
+++ "b/test_predictions.txt"
@@ -0,0 +1,14447 @@
+Context O
+Patients O
+with O
+pseudohypoparathyroidism O
+type O
+1b O
+( O
+PHP1b O
+) O
+show O
+disordered O
+imprinting O
+of O
+the O
+maternal O
+GNAS O
+allele O
+or O
+paternal O
+uniparental O
+disomy O
+( O
+UPD O
+) O
+. O
+
+Genetic O
+deletions O
+in O
+STX16 O
+or O
+in O
+upstream O
+exons O
+of O
+GNAS O
+are O
+present O
+in O
+many O
+familial O
+but O
+not O
+sporadic O
+cases O
+. O
+
+Objective O
+Characterization O
+of O
+epigenetic O
+and O
+genetic O
+defects O
+in O
+patients O
+with O
+PHP1b O
+. O
+
+Design O
+and O
+patients O
+DNA O
+from O
+84 O
+subjects O
+, O
+including O
+26 O
+subjects O
+with O
+sporadic O
+PHP1b O
+, O
+27 O
+affected O
+subjects O
+and O
+17 O
+unaffected O
+and/or O
+obligate O
+gene O
+carriers O
+from O
+12 O
+PHP1b O
+families O
+, O
+11 O
+healthy O
+individuals O
+, O
+and O
+3 O
+subjects O
+with O
+PHP1a O
+was O
+subjected O
+to O
+quantitative O
+pyrosequencing O
+of O
+GNAS O
+differentially O
+methylated O
+regions O
+( O
+DMRs O
+) O
+, O
+microarray O
+analysis O
+, O
+and O
+microsatellite O
+haplotype O
+analysis O
+. O
+
+Setting O
+Academic O
+medical O
+center O
+. O
+
+Main O
+outcome O
+measurements O
+Molecular O
+pathology O
+of O
+PHP1b O
+. O
+
+Results O
+Healthy O
+subjects O
+, O
+unaffected O
+family O
+members O
+and O
+obligate O
+carriers O
+of O
+paternal O
+PHP1b O
+alleles O
+, O
+and O
+subjects O
+with O
+PHP1a O
+showed O
+normal O
+methylation O
+of O
+all O
+DMRs O
+. O
+
+All O
+PHP1b O
+subjects O
+showed O
+loss O
+of O
+methylation O
+( O
+LOM O
+) O
+at O
+the O
+exon O
+A O
+/ O
+B O
+DMR O
+. O
+
+Affected O
+members O
+of O
+nine O
+PHP1b O
+kindreds O
+showed O
+LOM O
+only O
+at O
+the O
+exon O
+A O
+/ O
+B O
+DMR O
+, O
+which O
+was O
+associated O
+with O
+a O
+3 O
+- O
+kb O
+deletion O
+of O
+STX16 O
+exons O
+4 O
+- O
+6 O
+in O
+seven O
+families O
+and O
+a O
+novel O
+deletion O
+of O
+STX16 O
+and O
+adjacent O
+NEPEPL1 O
+in O
+one O
+family O
+. O
+
+A O
+novel O
+NESP O
+deletion O
+was O
+found O
+in O
+one O
+of O
+two O
+other O
+families O
+with O
+more O
+extensive O
+methylation O
+defects O
+. O
+
+One O
+sporadic O
+PHP1b O
+had O
+UPD O
+of O
+20q O
+, O
+two O
+had O
+3 O
+- O
+kb O
+STX16 O
+deletions O
+, O
+and O
+five O
+had O
+apparent O
+epigenetic O
+mosaicism O
+. O
+
+Conclusions O
+We O
+found O
+diverse O
+patterns O
+of O
+defective O
+methylation O
+and O
+identified O
+novel O
+or O
+previously O
+known O
+mutations O
+in O
+9 O
+of O
+12 O
+PHP1b O
+families O
+. O
+
+Malignancy O
+must O
+be O
+considered O
+in O
+the O
+management O
+of O
+adrenal O
+lesions O
+, O
+including O
+those O
+incidentally O
+identified O
+on O
+imaging O
+studies O
+. O
+
+Adrenocortical O
+carcinomas O
+( O
+ACCs O
+) O
+are O
+rare O
+tumors O
+with O
+an O
+estimated B-EPI
+annual I-EPI
+incidence I-EPI
+of O
+0.7 B-STAT
+- I-STAT
+2 I-STAT
+cases I-STAT
+per I-STAT
+year I-STAT
+and O
+a O
+worldwide B-LOC
+prevalence I-EPI
+of O
+4 B-STAT
+- I-STAT
+12 I-STAT
+cases I-STAT
+per I-STAT
+million I-STAT
+/ I-STAT
+year I-STAT
+. O
+
+However O
+, O
+a O
+much O
+higher O
+incidence B-EPI
+of O
+these O
+tumors O
+( O
+> O
+15 O
+times O
+) O
+has O
+been O
+demonstrated O
+in O
+south B-LOC
+and O
+southeastern I-LOC
+Brazil I-LOC
+. O
+
+Most O
+ACCs O
+cause O
+hypersecretion O
+of O
+steroids O
+including O
+glucocorticoids O
+and O
+androgens O
+. O
+
+ACC O
+patients O
+have O
+a O
+very O
+poor O
+prognosis O
+with O
+a O
+5 O
+- O
+year O
+overall O
+survival O
+( O
+OS O
+) O
+below O
+30 O
+% O
+in O
+most O
+series O
+. O
+
+Pheochromocytoma O
+or O
+paraganglioma O
+( O
+PPGL O
+) O
+is O
+a O
+metabolically O
+active O
+tumor O
+originating O
+from O
+the O
+chromaffin O
+cells O
+of O
+the O
+adrenal O
+medulla O
+. O
+
+The O
+incidence B-EPI
+of O
+PPGL O
+is O
+0.2 B-STAT
+to I-STAT
+0.9 I-STAT
+cases I-STAT
+per I-STAT
+100,000 I-STAT
+individuals I-STAT
+per I-STAT
+year I-STAT
+. O
+
+Pheochromocytomas O
+are O
+present O
+in O
+approximately O
+4 O
+- O
+7 O
+% O
+of O
+patients O
+with O
+adrenal O
+incidentalomas O
+. O
+
+Classically O
+, O
+PPGL O
+manifests O
+as O
+paroxysmal O
+attacks O
+of O
+the O
+following O
+4 O
+symptoms O
+: O
+headaches O
+, O
+diaphoresis O
+, O
+palpitations O
+, O
+and O
+severe O
+hypertensive O
+episodes O
+. O
+
+The O
+diagnosis O
+of O
+malignant O
+PPGL O
+relies O
+on O
+the O
+presence O
+of O
+local O
+invasion O
+or O
+metastasis O
+. O
+
+In O
+this O
+review O
+, O
+we O
+present O
+the O
+clinical O
+and O
+biochemical O
+characteristics O
+and O
+pathogenesis O
+of O
+malignant O
+primary O
+lesions O
+that O
+affect O
+the O
+cortex O
+and O
+medulla O
+of O
+human O
+adrenal O
+glands O
+. O
+
+Background O
+. O
+
+Human O
+T O
+- O
+cell O
+lymphotropic O
+virus O
+type O
+1 O
+( O
+HTLV-1 O
+) O
+is O
+responsible O
+for O
+tropical O
+spastic O
+paraparesis O
+and O
+HTLV-1 O
+- O
+associated O
+leukemia O
+/ O
+lymphoma O
+. O
+
+The O
+infection O
+is O
+endemic O
+in O
+some O
+areas O
+of O
+Peru B-LOC
+, O
+but O
+its O
+prevalence B-EPI
+in O
+the O
+Peruvian B-ETHN
+Amazon I-LOC
+is O
+not B-STAT
+well I-STAT
+established O
+. O
+
+We O
+aimed O
+to O
+assess O
+the O
+seroprevalence O
+of O
+HTLV-1 O
+infection O
+in O
+pregnant O
+women B-SEX
+in O
+the O
+Peruvian B-ETHN
+Amazon I-LOC
+. O
+
+Moreover O
+, O
+we O
+performed O
+a O
+systematic O
+literature O
+review O
+and O
+meta O
+- O
+analysis O
+of O
+the O
+seroprevalence O
+of O
+HTLV O
+infection O
+in O
+Peru B-LOC
+. O
+
+( O
+2 O
+) O
+Methods O
+. O
+
+This O
+is O
+a O
+prospective O
+cross O
+- O
+sectional O
+study O
+involving O
+pregnant O
+women B-SEX
+attending O
+health O
+centers O
+in O
+the O
+city O
+of O
+Iquitos B-LOC
+, I-LOC
+Peru I-LOC
+, O
+in O
+May B-DATE
+and I-DATE
+June I-DATE
+2019 I-DATE
+. O
+
+The O
+presence O
+of O
+antibodies O
+against O
+HTLV-1 O
+was O
+assessed O
+using O
+ELISA O
+( O
+HTLV O
+I O
++ O
+II O
+ELISA O
+recombinant O
+v.4.0 O
+, O
+Wiener O
+lab O
+, O
+Rosario B-LOC
+, I-LOC
+Argentina I-LOC
+) O
+. O
+
+Positive O
+cases O
+were O
+confirmed O
+by O
+Western O
+Blot O
+and O
+HTLV-1 O
+proviral O
+load O
+. O
+
+( O
+3 O
+) O
+Results O
+. O
+
+The O
+study O
+included O
+300 O
+pregnant O
+women B-SEX
+with O
+a O
+mean O
+age O
+of O
+26 O
+years O
+( O
+standard O
+deviation O
+[ O
+SD O
+] O
+6.4 O
+) O
+. O
+
+Five O
+patients O
+were O
+diagnosed O
+with O
+HTLV-1 O
+infection O
+( O
+prevalence B-EPI
+1.7 B-STAT
+% I-STAT
+, O
+95 O
+% O
+confidence O
+interval O
+( O
+CI O
+) O
+0.7 O
+% O
+to O
+3.8 O
+% O
+) O
+. O
+
+Pregnant O
+women B-SEX
+with O
+HTLV-1 O
+infection O
+were O
+discretely O
+younger O
+( O
+mean O
+age O
+22.6 O
+[ O
+SD O
+22.6 O
+] O
+vs O
+26.8 O
+[ O
+SD O
+6.3 O
+] O
+; O
+p O
+= O
+0.128 O
+) O
+. O
+
+None O
+of O
+the O
+five O
+women B-SEX
+had O
+been O
+transfused O
+, O
+and O
+all O
+were O
+asymptomatic O
+. O
+
+Two O
+( O
+40 O
+% O
+) O
+also O
+had O
+a O
+positive O
+serology O
+for O
+Strongyloides O
+, O
+but O
+larvae O
+were O
+not O
+detected O
+in O
+any O
+of O
+the O
+parasitological O
+stool O
+studies O
+. O
+
+The O
+systematic O
+review O
+component O
+identified O
+40 O
+studies O
+, O
+which O
+showed O
+that O
+the O
+prevalence B-EPI
+of O
+HTLV O
+infection O
+in O
+the O
+general O
+population O
+was O
+2.9 O
+% O
+( O
+95 O
+% O
+CI O
+1.2 O
+% O
+to O
+5.3 O
+% O
+) O
+and O
+in O
+women B-SEX
+of O
+childbearing O
+age O
+, O
+2.5 O
+% O
+( O
+95 O
+% O
+CI O
+1.2 O
+% O
+to O
+4.0 O
+% O
+) O
+. O
+
+( O
+4 O
+) O
+Conclusion O
+. O
+
+The O
+prevalence B-EPI
+of O
+HTLV-1 O
+in O
+the B-LOC
+Peruvian B-LOC
+Amazon I-LOC
+basin I-LOC
+is O
+about O
+1.7 O
+% O
+, O
+indicating O
+an O
+endemic O
+presence O
+. O
+
+Screening O
+for O
+HTLV-1 O
+in O
+prenatal O
+care O
+is O
+warranted O
+. O
+
+Background O
+Comorbidity O
+may O
+influence O
+clinical O
+aspects O
+of O
+neuromyelitis O
+optica O
+spectrum O
+disorder O
+( O
+NMOSD O
+) O
+. O
+
+We O
+estimated O
+the O
+prevalence B-EPI
+of O
+comorbidities O
+to O
+assess O
+their O
+association O
+with O
+outcomes O
+. O
+
+Methods O
+This O
+retrospective O
+study O
+assessed O
+records O
+of O
+NMOSD O
+patients O
+from O
+2008 B-DATE
+to I-DATE
+2019 I-DATE
+, O
+categorizing O
+comorbidities O
+into O
+three O
+groups O
+: O
+somatic O
+, O
+psychiatric O
+and O
+autoimmune O
+. O
+
+Severity O
+of O
+disease O
+was O
+evaluated O
+by O
+the O
+Expanded O
+Disability O
+Status O
+Scale O
+, O
+progression O
+index O
+( O
+PI O
+) O
+and O
+annualized O
+relapse O
+rate O
+. O
+
+The O
+frequency O
+of O
+comorbidities O
+was O
+compared O
+between O
+anti O
+- O
+aquaporin O
+4 O
+antibody O
+( O
+AQP4 O
+- O
+IgG O
+) O
+seropositive O
+and O
+seronegative O
+patients O
+. O
+
+Results O
+A O
+total O
+of O
+67 O
+NMOSD O
+patients O
+were O
+enrolled O
+. O
+
+Thirty O
+- O
+five O
+( O
+52.2 O
+% O
+) O
+patients O
+reported O
+at O
+least O
+one O
+comorbidity O
+. O
+
+In O
+total O
+, O
+44 O
+comorbidities O
+were O
+found O
+, O
+of O
+which O
+24 O
+occurred O
+prior O
+to O
+NMOSD O
+onset O
+: O
+29 O
+somatic O
+, O
+13 O
+psychiatric O
+and O
+2 O
+autoimmune O
+entities O
+. O
+
+The O
+most O
+common O
+comorbidities O
+were O
+anxiety O
+disorders O
+7/67 O
+( O
+10.4 O
+% O
+) O
+, O
+followed O
+by O
+migraine O
+6/67 O
+( O
+8.9 O
+% O
+) O
+major O
+depression O
+disorder O
+6/67 O
+( O
+8.9 O
+% O
+) O
+, O
+iron O
+deficiency O
+anemia O
+8/54 O
+( O
+14.8 O
+% O
+) O
+, O
+and O
+non O
+- O
+autoimmune O
+hypothyroidism O
+4/67 O
+( O
+6.0 O
+% O
+) O
+. O
+
+Psychiatric O
+comorbidities O
+associated O
+with O
+PI O
+in O
+unadjusted O
+( O
+OR=0.538 O
+, O
+95 O
+% O
+CI=0.141 O
+, O
+0.935 O
+, O
+P=0.009 O
+) O
+and O
+adjusted O
+models O
+( O
+OR=0.386 O
+, O
+95 O
+% O
+CI=0.022 O
+, O
+0.751 O
+, O
+P=0.038 O
+) O
+. O
+
+A O
+significantly O
+higher O
+frequency O
+of O
+psychiatric O
+comorbidities O
+was O
+observed O
+in O
+the O
+AQP4 O
+- O
+IgG O
+positive O
+patients O
+( O
+P=0.031 O
+) O
+. O
+
+Conclusion O
+Half O
+of O
+the O
+patients O
+had O
+comorbidities O
+, O
+suggesting O
+screening O
+for O
+comorbidity O
+as O
+part O
+of O
+NMOSD O
+care O
+. O
+
+The O
+psychiatric O
+comorbidities O
+had O
+impact O
+on O
+clinical O
+outcome O
+. O
+
+Aberrant O
+right O
+subclavian O
+artery O
+( O
+ARSA O
+) O
+, O
+the O
+most O
+common O
+aortic O
+arch O
+abnormality O
+, O
+occurs B-EPI
+in O
+approximately B-STAT
+0.5 B-STAT
+to I-STAT
+1.8 I-STAT
+% I-STAT
+of O
+the O
+general O
+population O
+, O
+with O
+prevalence B-EPI
+of O
+up O
+to O
+25 I-STAT
+% I-STAT
+in O
+those O
+with O
+esophageal O
+atresia O
+. O
+
+Although O
+ARSA O
+is O
+often O
+asymptomatic O
+, O
+a O
+fistulous O
+tract O
+into O
+esophagus O
+may O
+develop O
+with O
+prolonged O
+nasogastric O
+tube O
+placement O
+or O
+endotracheal O
+intubation O
+and O
+lead O
+to O
+potentially O
+fatal O
+hematemesis O
+. O
+
+We O
+present O
+a O
+first O
+case O
+of O
+ARSA O
+- O
+esophageal O
+fistula O
+in O
+a O
+20 O
+- O
+year O
+- O
+old O
+woman B-SEX
+with O
+VATER O
+association O
+in O
+the O
+absence O
+of O
+an O
+esophageal O
+anomaly O
+and O
+review O
+28 O
+cases O
+of O
+ARSA O
+- O
+esophageal O
+fistula O
+reported O
+in O
+the O
+literature O
+to O
+date O
+. O
+
+Requiring O
+nasogastric O
+and O
+endotracheal O
+tube O
+placement O
+for O
+approximately O
+4 O
+months O
+, O
+the O
+patient O
+had O
+a O
+prolonged O
+hospital O
+course O
+and O
+died O
+after O
+sudden O
+hematemesis O
+. O
+
+An O
+autopsy O
+demonstrated O
+an O
+ARSA O
+- O
+esophageal O
+fistula O
+and O
+no O
+other O
+source O
+of O
+upper O
+gastrointestinal O
+bleeding O
+. O
+
+In O
+patients O
+with O
+esophageal O
+atresia O
+requiring O
+prolonged O
+placement O
+of O
+an O
+endotracheal O
+or O
+nasogastric O
+tube O
+, O
+a O
+screening O
+imaging O
+study O
+and O
+corrective O
+surgery O
+may O
+be O
+indicated O
+. O
+
+Although O
+the O
+mortality O
+rate O
+is O
+still O
+high O
+, O
+timely O
+recognition O
+and O
+repair O
+of O
+ARSA O
+- O
+esophageal O
+fistula O
+appear O
+to O
+be O
+improving O
+. O
+
+Given O
+the O
+potentially O
+prolonged O
+latency O
+for O
+its O
+development O
+with O
+occasional O
+presence O
+of O
+heralding O
+symptoms O
+, O
+increased O
+awareness O
+may O
+facilitate O
+surgical O
+intervention O
+to O
+prevent O
+a O
+catastrophic O
+exsanguination O
+. O
+
+The O
+reported O
+incidence B-EPI
+of O
+COVID-19 O
+among O
+cohorts O
+of O
+patients O
+with O
+inflammatory O
+bowel O
+and O
+skin O
+diseases O
+under O
+treatment O
+with O
+biologicals O
+is O
+low O
+. O
+
+Treatment O
+may O
+further O
+modify O
+disease O
+severity O
+as O
+some O
+biological O
+modifiers O
+, O
+such O
+as O
+anakinra O
+, O
+are O
+also O
+proposed O
+for O
+the O
+management O
+of O
+COVID-19 O
+patients O
+potentially O
+providing O
+HS O
+patients O
+with O
+an O
+advantage O
+. O
+
+The O
+above O
+preliminary O
+evidence O
+suggests O
+that O
+hidradenitis O
+suppurativa O
+( O
+HS O
+) O
+does O
+probably O
+not O
+provide O
+an O
+increased O
+susceptibility O
+for O
+COVID-19 O
+and O
+that O
+any O
+susceptibility O
+is O
+unlikely O
+to O
+be O
+modified O
+negatively O
+by O
+treatment O
+with O
+biologicals O
+. O
+
+On O
+the O
+occasion O
+of O
+its O
+10th O
+International O
+Conference O
+, O
+experts O
+of O
+the O
+European O
+Hidradenitis O
+Suppurativa O
+Foundation O
+e. O
+V. O
+
+have O
+prepared O
+a O
+consensus O
+statement O
+regarding O
+anti O
+- O
+COVID-19 O
+measurements O
+for O
+HS O
+patients O
+. O
+
+Based O
+on O
+the O
+available O
+knowledge O
+, O
+patients O
+with O
+HS O
+may O
+be O
+vaccinated O
+against O
+SARS O
+- O
+CoV2 O
+and O
+patients O
+affected O
+by O
+metabolic O
+syndrome O
+constitute O
+a O
+high O
+- O
+risk O
+group O
+for O
+COVID-19 O
+and O
+should O
+be O
+vaccinated O
+at O
+the O
+earliest O
+convenient O
+point O
+in O
+time O
+. O
+
+HS O
+patients O
+on O
+treatment O
+with O
+adalimumab O
+can O
+be O
+vaccinated O
+with O
+non O
+- O
+living O
+virus O
+anti O
+- O
+SARS O
+- O
+CoV2 O
+vaccines O
+. O
+
+A O
+possible O
+suboptimal O
+effect O
+of O
+the O
+vaccine O
+may O
+be O
+suspected O
+but O
+might O
+not O
+be O
+expected O
+universally O
+. O
+
+The O
+management O
+of O
+the O
+biological O
+treatment O
+in O
+HS O
+patients O
+is O
+at O
+the O
+discretion O
+of O
+the O
+dermatologist O
+/ O
+responsible O
+physician O
+. O
+
+Over O
+the O
+last O
+two O
+decades O
+, O
+improvements O
+in O
+perinatology O
+have O
+led O
+to O
+increased O
+survival O
+rates O
+of O
+preterm O
+infants O
+. O
+
+A O
+large O
+number O
+of O
+studies O
+and O
+meta O
+- O
+analyses O
+have O
+investigated O
+of O
+preterm O
+infants O
+and/or O
+the O
+influence O
+of O
+developmental O
+care O
+. O
+
+However O
+, O
+the O
+combined O
+influence O
+of O
+the O
+most O
+frequent O
+risk O
+factors O
+and O
+developmental O
+care O
+on O
+the O
+long O
+- O
+term O
+somatic O
+, O
+motor O
+, O
+and O
+cognitive O
+outcome O
+of O
+preterm O
+infants O
+remains O
+unclear O
+. O
+
+This O
+retrospective O
+, O
+single O
+- O
+center O
+cohort O
+study O
+includes O
+256 O
+children O
+treated O
+in O
+a O
+tertiary O
+neonatal O
+intensive O
+care O
+unit O
+in O
+Rostock B-LOC
+, O
+Germany B-LOC
+, O
+between B-DATE
+2008 I-DATE
+and I-DATE
+2013 I-DATE
+. O
+
+Follow O
+- O
+up O
+examinations O
+( O
+somatic O
+, O
+psychomotor O
+, O
+and O
+mental O
+development O
+) O
+were O
+performed O
+at O
+( O
+corrected O
+) O
+24 O
+months O
+using O
+Bayley O
+Scales O
+of O
+Infant O
+Development O
+II O
+( O
+BSID O
+- O
+II O
+) O
+. O
+
+Developmental O
+care O
+was O
+carried O
+out O
+according O
+to O
+the O
+legal O
+framework O
+and O
+national O
+guidelines O
+( O
+physiotherapy O
+and/or O
+early O
+education O
+) O
+. O
+
+Bronchopulmonary O
+dysplasia O
+( O
+BPD O
+) O
+and O
+an O
+exclusive O
+formula O
+feeding O
+showed O
+a O
+2.8 O
+- O
+4.6 O
+- O
+fold O
+higher O
+risk O
+( O
+95 O
+% O
+Confidence O
+Interval O
+: O
+Mental O
+Developmental O
+Index O
+1.73 O
+- O
+7.58 O
+; O
+Psychomotor O
+Developmental O
+Index O
+1.44 O
+- O
+14.54 O
+; O
+body O
+length O
+1.20 O
+- O
+6.41 O
+) O
+for O
+developmental O
+deficits O
+( O
+mental O
+and O
+psychomotor O
+developmental O
+index O
+; O
+body O
+length O
+) O
+. O
+
+Developmental O
+care O
+after O
+discharge O
+according O
+to O
+national O
+guidelines O
+did O
+not O
+prevent O
+this O
+. O
+
+Since O
+this O
+is O
+a O
+retrospective O
+pilot O
+study O
+, O
+no O
+recommendations O
+can O
+be O
+made O
+based O
+on O
+this O
+analysis O
+. O
+
+Therefore O
+, O
+future O
+research O
+should O
+evaluate O
+whether O
+standard O
+developmental O
+care O
+should O
+be O
+extended O
+by O
+tailored O
+measures O
+depending O
+on O
+individual O
+risk O
+factors O
+. O
+
+Abstract O
+Previous O
+studies O
+have O
+suggested O
+that O
+human O
+T O
+- O
+cell O
+leukemia O
+virus O
+type O
+1 O
+( O
+HTLV-1 O
+) O
+might O
+act O
+as O
+a O
+pathogen O
+in O
+rheumatoid O
+arthritis O
+( O
+RA O
+) O
+, O
+but O
+epidemiological O
+evidence O
+of O
+an O
+association O
+is O
+scarce O
+. O
+
+We O
+measured O
+anti O
+- O
+HTLV-1 O
+antibodies O
+among O
+Nagasaki B-LOC
+atomic O
+bomb O
+survivors O
+to O
+determine O
+whether O
+HTLV-1 O
+is O
+related O
+to O
+RA O
+and O
+whether O
+radiation O
+exposure O
+is O
+associated O
+with O
+HTLV-1 O
+and O
+RA O
+prevalence B-EPI
+. O
+This O
+is O
+a O
+cross O
+- O
+sectional O
+study O
+among O
+atomic O
+bomb O
+survivors O
+who O
+participated O
+in O
+biennial O
+health O
+examinations O
+from O
+2006 B-DATE
+to I-DATE
+2010 I-DATE
+. O
+
+Serum O
+levels O
+of O
+anti O
+- O
+HTLV-1 O
+antibodies O
+were O
+measured O
+using O
+a O
+chemiluminescent O
+enzyme O
+immunoassay O
+and O
+confirmed O
+by O
+Western O
+blotting O
+. O
+
+Association O
+between O
+HTLV-1 O
+and O
+RA O
+was O
+analyzed O
+by O
+a O
+logistic O
+regression O
+model O
+. O
+Of O
+2091 O
+participants O
+( O
+women B-SEX
+61.5 O
+% O
+; O
+median O
+age O
+, O
+73 O
+years O
+) O
+, O
+215 O
+( O
+10.3 O
+% O
+) O
+had O
+anti O
+- O
+HTLV-1 O
+antibodies O
+. O
+
+HTLV-1 O
+prevalence B-EPI
+was O
+higher O
+among O
+women B-SEX
+( O
+13.1 O
+% O
+vs O
+5.8 O
+% O
+; O
+P O
+< O
+.001 O
+) O
+. O
+
+Twenty O
+- O
+two O
+participants O
+( O
+1.1 O
+% O
+) O
+were O
+diagnosed O
+with O
+RA O
+. O
+
+HTLV-1 O
+prevalence B-EPI
+among O
+RA O
+participants O
+was O
+significantly O
+higher O
+than O
+that O
+among O
+non O
+- O
+RA O
+participants O
+( O
+27.3 O
+% O
+vs O
+10.1 O
+% O
+; O
+P O
+= O
+.020 O
+) O
+. O
+
+After O
+adjustment O
+for O
+age O
+, O
+sex O
+, O
+and O
+hepatitis O
+C O
+virus O
+infection O
+, O
+HTLV-1 O
+was O
+significantly O
+associated O
+with O
+prevalent B-EPI
+RA O
+( O
+odds O
+ratio O
+, O
+2.89 O
+; O
+95 O
+% O
+confidence O
+interval O
+, O
+1.06 O
+, O
+7.03 O
+) O
+. O
+
+There O
+was O
+no O
+association O
+between O
+radiation O
+dose O
+and O
+either O
+the O
+prevalence B-EPI
+of O
+HTLV-1 O
+or O
+RA O
+. O
+
+This O
+study O
+, O
+among O
+a O
+well O
+- O
+defined O
+group O
+of O
+atomic O
+bomb O
+survivors O
+, O
+suggests O
+that O
+HTLV-1 O
+is O
+associated O
+with O
+RA O
+. O
+
+A O
+study O
+of O
+parental O
+cancer O
+in O
+326 O
+children O
+referred O
+to O
+a O
+single O
+Paediatric O
+Oncology O
+Unit O
+found O
+a O
+significant O
+increase O
+in O
+breast O
+cancer O
+in O
+mothers O
+of O
+children O
+with O
+solid O
+tumours O
+. O
+
+The O
+5 O
+tumours O
+found O
+were O
+8.9 O
+times O
+the O
+expected O
+number O
+. O
+
+This O
+increase O
+could O
+not O
+be O
+accounted O
+for O
+by O
+any O
+of O
+the O
+known O
+risk O
+factors O
+for O
+breast O
+cancer O
+. O
+
+The O
+incidence B-EPI
+of O
+cancer O
+in O
+mothers O
+of O
+leukaemic O
+children O
+and O
+in O
+all O
+groups O
+of O
+fathers O
+was O
+not O
+significantly O
+raised O
+. O
+
+Further O
+prospective O
+studies O
+in O
+the O
+mothers O
+of O
+young O
+children O
+with O
+soft O
+tissue O
+tumours O
+are O
+needed O
+to O
+clarify O
+the O
+groups O
+at O
+risk O
+and O
+to O
+determine O
+whether O
+counselling O
+and O
+surveillance O
+of O
+these O
+mothers O
+is O
+appropriate O
+. O
+
+Background O
+Vitamin O
+C O
+has O
+anti O
+- O
+oxidant O
+properties O
+and O
+acts O
+as O
+a O
+cofactor O
+for O
+several O
+enzymes O
+. O
+
+Hypovitaminosis O
+C O
+has O
+been O
+associated O
+with O
+bleeding O
+, O
+endothelial O
+dysfunction O
+and O
+death O
+. O
+
+The O
+prevalence B-EPI
+of O
+hypovitaminosis O
+C O
+is O
+unknown O
+in O
+Australian B-ETHN
+hospitalised O
+patients O
+, O
+and O
+its O
+clinical O
+relevance O
+is O
+uncertain O
+. O
+
+Aims O
+To O
+determine O
+the O
+prevalence B-EPI
+, O
+characteristics O
+and O
+clinical O
+outcomes O
+of O
+hospitalised O
+patients O
+with O
+hypovitaminosis O
+C. O
+
+Methods O
+This O
+observational O
+study O
+included O
+general O
+- O
+medical O
+inpatients O
+in O
+a O
+tertiary O
+- O
+level O
+hospital O
+in O
+Australia B-LOC
+. O
+
+High O
+- O
+performance O
+liquid O
+chromatography O
+( O
+HPLC O
+) O
+was O
+used O
+to O
+determine O
+plasma O
+vitamin O
+C O
+levels O
+. O
+
+As O
+per O
+Johnston O
+'s O
+criteria O
+, O
+vitamin O
+C O
+levels O
+of O
+≥ O
+28.0 O
+μmol O
+/ O
+L O
+were O
+classified O
+as O
+normal O
+and O
+< O
+28 O
+μmol O
+/ O
+L O
+as O
+low O
+. O
+
+Clinical O
+outcomes O
+determined O
+included O
+length O
+of O
+hospital O
+stay O
+( O
+LOS O
+) O
+, O
+nosocomial O
+complications O
+, O
+intensive O
+care O
+unit O
+admission O
+and O
+in O
+- O
+hospital O
+mortality O
+. O
+
+Results O
+A O
+total O
+of O
+200 O
+patients O
+participated O
+in O
+this O
+study O
+, O
+and O
+vitamin O
+C O
+levels O
+were O
+available O
+for O
+149 O
+patients O
+, O
+of O
+whom O
+35 O
+( O
+23.5 O
+% O
+) O
+had O
+normal O
+vitamin O
+C O
+levels O
+, O
+and O
+114 O
+( O
+76.5 O
+% O
+) O
+had O
+hypovitaminosis O
+C. O
+
+Patients O
+with O
+hypovitaminosis O
+C O
+were O
+older O
+and O
+had O
+higher O
+C O
+- O
+reactive O
+protein O
+( O
+CRP O
+) O
+levels O
+. O
+
+Median O
+LOS O
+was O
+2 O
+days O
+longer O
+in O
+patients O
+with O
+hypovitaminosis O
+C O
+( O
+6 O
+days O
+( O
+interquartile O
+range O
+( O
+IQR O
+) O
+4 O
+, O
+8) O
+vs O
+4 O
+days O
+( O
+IQR O
+3 O
+, O
+6 O
+) O
+, O
+P O
+= O
+0.02 O
+) O
+, O
+and O
+they O
+had O
+fourfold O
+higher O
+odds O
+of O
+staying O
+in O
+hospital O
+for O
+> O
+5 O
+days O
+than O
+those O
+with O
+normal O
+vitamin O
+C O
+levels O
+. O
+
+Other O
+clinical O
+outcomes O
+were O
+similar O
+between O
+the O
+two O
+groups O
+. O
+
+Conclusions O
+Hypovitaminosis O
+C O
+is O
+common O
+in O
+hospitalised O
+patients O
+and O
+is O
+associated O
+with O
+prolonged O
+LOS O
+. O
+
+Further O
+research O
+is O
+needed O
+to O
+ascertain O
+the O
+benefits O
+of O
+vitamin O
+C O
+supplementation O
+in O
+vitamin O
+C O
+- O
+depleted O
+patients O
+. O
+
+We O
+have O
+previously O
+shown O
+that O
+67 O
+% O
+of O
+patients O
+with O
+newly O
+diagnosed O
+coeliac O
+disease O
+( O
+CD O
+) O
+presenting O
+to O
+gastroenterologists O
+have O
+evidence O
+of O
+neurological O
+dysfunction O
+. O
+
+This O
+manifested O
+with O
+headache O
+and O
+loss O
+of O
+co O
+- O
+ordination O
+. O
+
+Furthermore O
+60 O
+% O
+of O
+these O
+patients O
+had O
+abnormal O
+brain O
+imaging O
+. O
+
+In O
+this O
+follow O
+- O
+up O
+study O
+, O
+we O
+re O
+- O
+examined O
+and O
+re O
+- O
+scanned O
+30 O
+patients O
+from O
+the O
+original O
+cohort O
+of O
+100 O
+, O
+seven O
+years O
+later O
+. O
+
+There O
+was O
+significant O
+reduction O
+in O
+the O
+prevalence B-EPI
+of O
+headaches O
+( O
+47 O
+% O
+to O
+20 O
+% O
+) O
+but O
+an O
+increase O
+in O
+the O
+prevalence B-EPI
+of O
+incoordination O
+( O
+27 O
+% O
+to O
+47 O
+% O
+) O
+. O
+
+Although O
+those O
+patients O
+with O
+coordination O
+problems O
+at O
+baseline O
+reported O
+improvement O
+on O
+the O
+gluten O
+free O
+diet O
+( O
+GFD O
+) O
+, O
+there O
+were O
+7 O
+patients O
+reporting O
+incoordination O
+not O
+present O
+at O
+baseline O
+. O
+
+All O
+7 O
+patients O
+had O
+positive O
+serology O
+for O
+one O
+or O
+more O
+gluten O
+- O
+sensitivity O
+related O
+antibodies O
+at O
+follow O
+- O
+up O
+. O
+
+In O
+total O
+, O
+50 O
+% O
+of O
+the O
+whole O
+follow O
+- O
+up O
+cohort O
+were O
+positive O
+for O
+one O
+or O
+more O
+gluten O
+- O
+related O
+antibodies O
+. O
+
+A O
+comparison O
+between O
+the O
+baseline O
+and O
+follow O
+- O
+up O
+brain O
+imaging O
+showed O
+a O
+greater O
+rate O
+of O
+cerebellar O
+grey O
+matter O
+atrophy O
+in O
+the O
+antibody O
+positive O
+group O
+compared O
+to O
+the O
+antibody O
+negative O
+group O
+. O
+
+Patients O
+with O
+CD O
+who O
+do O
+not O
+adhere O
+to O
+a O
+strict O
+GFD O
+and O
+are O
+serological O
+positive O
+are O
+at O
+risk O
+of O
+developing O
+ataxia O
+, O
+and O
+have O
+a O
+significantly O
+higher O
+rate O
+of O
+cerebellar O
+atrophy O
+when O
+compared O
+to O
+patients O
+with O
+negative O
+serology O
+. O
+
+This O
+highlights O
+the O
+importance O
+of O
+regular O
+review O
+and O
+close O
+monitoring O
+. O
+
+Background O
+To O
+evaluate O
+the O
+relationship O
+between O
+gender O
+, O
+ethnicity O
+/ O
+citizenship O
+, O
+clinical O
+phenotype O
+, O
+total B-EPI
+prevalence I-EPI
+, O
+and O
+the O
+various O
+congenital O
+malformations O
+associated O
+with O
+oral O
+clefts O
+( O
+OC O
+) O
+in O
+Italy B-LOC
+across O
+the O
+period O
+2001 B-DATE
+- I-DATE
+2014 I-DATE
+. O
+
+Methods O
+A O
+retrospective O
+analysis O
+( O
+2001 B-DATE
+- I-DATE
+2014 I-DATE
+) O
+was O
+conducted O
+based O
+on O
+the O
+National O
+Congenital O
+Malformation O
+Registries O
+network O
+of O
+Italy B-LOC
+( O
+Emilia B-LOC
+- O
+Romagna O
+Registry O
+of O
+Birth O
+Defects O
+[ O
+IMER O
+] O
+and O
+Registro O
+Toscano O
+Difetti O
+Congeniti O
+[ O
+RTDC O
+] O
+) O
+, O
+which O
+were O
+analyzed O
+to O
+investigate O
+time O
+trends O
+, O
+geographical O
+/ O
+ethnic O
+clusters O
+, O
+topography O
+, O
+sex O
+ratio O
+, O
+and O
+associated O
+congenital O
+anomalies O
+of O
+OC O
+phenotypes O
+. O
+
+Results O
+Among O
+739 O
+registered O
+cases O
+, O
+29.8 O
+% O
+were O
+syndromic O
+or O
+had O
+multi O
+- O
+malformed O
+associated O
+anomalies O
+, O
+compared O
+with O
+70.2 O
+% O
+having O
+isolated O
+orofacial O
+cleft O
+. O
+
+Cleft O
+lip O
+( O
+CL O
+) O
+was O
+observed O
+in O
+22 O
+% O
+, O
+cleft O
+palate O
+( O
+CP O
+) O
+in O
+40 O
+% O
+, O
+and O
+cleft O
+lip O
+and O
+palate O
+( O
+CLP O
+) O
+in O
+38 O
+% O
+of O
+live O
+births O
+, O
+stillbirths O
+, O
+and O
+terminations O
+of O
+pregnancy O
+for O
+fetal O
+anomaly O
+cases O
+. O
+
+Other O
+associated O
+conditions O
+were O
+major O
+anomalies O
+of O
+cardiovascular O
+defects O
+( O
+39 O
+% O
+) O
+, O
+followed O
+by O
+defects O
+of O
+the O
+limbs O
+( O
+28 O
+% O
+) O
+, O
+neuroectodermal O
+defects O
+( O
+23 O
+% O
+) O
+, O
+and O
+urogenital O
+malformations O
+( O
+10 O
+% O
+) O
+. O
+
+Male B-SEX
+- O
+to O
+- O
+female B-SEX
+sex O
+ratio O
+was O
+1:1.14 O
+in O
+CP O
+, O
+1.22:1 O
+in O
+CL O
+, O
+and O
+1.9:1 O
+in O
+CLP O
+. O
+
+Foreigners O
+were O
+represented O
+by O
+29 O
+% O
+from O
+Southeast B-LOC
+Asia I-LOC
+, O
+25 O
+% O
+from O
+Balkans B-LOC
+, O
+25 O
+% O
+from O
+North B-LOC
+- I-LOC
+Central I-LOC
+Africa I-LOC
+, O
+9 O
+% O
+from O
+the O
+East I-LOC
+, O
+7 O
+% O
+from O
+Western B-LOC
+Europe I-LOC
+, O
+and O
+5 O
+% O
+from O
+South B-LOC
+America I-LOC
+. O
+
+Total B-EPI
+prevalence I-EPI
+of O
+OC O
+cases O
+ranged O
+from O
+0.9 B-STAT
+( O
+RTDC O
+) O
+to I-STAT
+1.1 I-STAT
+( O
+IMER O
+) O
+of I-STAT
+1000 I-STAT
+births I-STAT
+. O
+
+Conclusions O
+This O
+retrospective O
+study O
+provides O
+a O
+population O
+- O
+based O
+, O
+clinical O
+- O
+epidemiological O
+description O
+of O
+the O
+orofacial O
+cleft O
+phenomenon O
+. O
+
+As O
+a O
+relatively O
+frequent O
+congenital O
+malformation O
+, O
+its O
+social O
+and O
+economic O
+impact O
+is O
+worthy O
+of O
+further O
+study O
+. O
+
+These O
+abnormalities O
+can O
+cause O
+significant O
+problems O
+that O
+may O
+be O
+solved O
+or O
+minimized O
+by O
+early O
+diagnosis O
+and O
+treatment O
+. O
+
+Rates O
+of O
+eating O
+disorders O
+( O
+EDs O
+) O
+are O
+increasing O
+in O
+Australia B-LOC
+, O
+as O
+are O
+rates O
+of O
+bariatric O
+and O
+cosmetic O
+surgery O
+including O
+weight O
+- O
+related O
+procedures O
+. O
+
+It O
+is O
+known O
+that O
+binge O
+eating O
+disorder O
+( O
+BED O
+) O
+is O
+common O
+in O
+bariatric O
+surgery O
+candidates O
+and O
+that O
+people O
+with O
+EDs O
+are O
+likely O
+to O
+undergo O
+weight O
+- O
+related O
+cosmetic O
+procedures O
+, O
+however O
+, O
+most O
+of O
+the O
+literature O
+is O
+based O
+on O
+clinic O
+samples O
+and O
+focuses O
+on O
+young O
+women B-SEX
+and O
+BED O
+. O
+
+Aims O
+of O
+this O
+study O
+were O
+to O
+determine O
+the O
+prevalence B-EPI
+of O
+( O
+1 O
+) O
+actual O
+or O
+intended O
+bariatric O
+surgery O
+and O
+( O
+2 O
+) O
+actual O
+or O
+intended O
+cosmetic O
+surgery O
+including O
+weight O
+- O
+related O
+procedures O
+in O
+people O
+with O
+a O
+current O
+ED O
+and O
+a O
+lifetime O
+history O
+of O
+BED O
+or O
+bulimia O
+nervosa O
+( O
+BN O
+) O
+, O
+and O
+the O
+associations O
+with O
+actual O
+or O
+intended O
+bariatric O
+or O
+cosmetic O
+surgery O
+and O
+demographic O
+features O
+. O
+
+Using O
+a O
+general O
+population O
+survey O
+, O
+2977 O
+individuals O
+were O
+interviewed O
+regarding O
+sociodemographic O
+status O
+, O
+ED O
+symptoms O
+, O
+mental O
+health O
+- O
+related O
+quality O
+of O
+life O
+( O
+MHRQoL O
+) O
+and O
+actual O
+or O
+intended O
+use O
+of O
+bariatric O
+and O
+cosmetic O
+surgery O
+, O
+prevalence B-EPI
+estimates I-EPI
+of O
+which O
+were O
+2.0 B-STAT
+% I-STAT
+and O
+1.1 B-STAT
+% I-STAT
+, O
+respectively O
+. O
+
+People O
+who O
+had O
+planned O
+or O
+received O
+either O
+type O
+of O
+surgery O
+were O
+more O
+likely O
+to O
+be O
+( O
+1 O
+) O
+women B-SEX
+and O
+( O
+2 O
+) O
+have O
+a O
+higher O
+BMI O
+, O
+( O
+3 O
+) O
+poorer O
+MHRQoL O
+and O
+( O
+4 O
+) O
+a O
+current O
+ED O
+, O
+lifetime O
+BN O
+or O
+BED O
+or O
+features O
+of O
+EDs O
+( O
+all O
+p O
+< O
+0.05 O
+) O
+. O
+
+Age O
+and O
+household O
+income O
+were O
+not O
+significantly O
+associated O
+with O
+increased O
+use O
+of O
+either O
+type O
+of O
+surgery O
+. O
+
+Given O
+the O
+potential O
+for O
+an O
+ED O
+to O
+affect O
+outcomes O
+of O
+surgery O
+, O
+screening O
+and O
+treatment O
+for O
+EDs O
+should O
+be O
+considered O
+in O
+such O
+surgical O
+candidates O
+. O
+
+Congenital O
+adrenal O
+hyperplasia O
+( O
+CAH O
+) O
+was O
+the O
+fourth O
+disorder O
+added O
+to O
+the O
+national O
+Swedish B-ETHN
+neonatal O
+screening O
+program O
+in O
+1986 B-DATE
+, O
+and O
+approximately O
+115,000 O
+newborns O
+are O
+screened O
+annually O
+. O
+
+Dried O
+blood O
+spot O
+( O
+DBS O
+) O
+screening O
+with O
+measurement O
+of O
+17 O
+- O
+hydroxyprogesterone O
+( O
+17OHP O
+) O
+is O
+also O
+offered O
+to O
+older O
+children O
+moving O
+to O
+Sweden B-LOC
+from O
+countries O
+lacking O
+a O
+national O
+DBS O
+screening O
+program O
+. O
+
+Here O
+, O
+we O
+report O
+an O
+update O
+on O
+the O
+CAH O
+screening O
+from O
+January B-DATE
+2011 I-DATE
+until I-DATE
+December I-DATE
+2019 I-DATE
+. O
+
+Results O
+: O
+During O
+the O
+study O
+period O
+, O
+1,030,409 O
+newborns O
+and O
+34,713 O
+older O
+children O
+were O
+screened O
+. O
+
+In O
+total O
+, O
+87 O
+newborns O
+were O
+verified O
+to O
+have O
+CAH O
+, O
+which O
+gives O
+an O
+overall O
+positive O
+predictive O
+value O
+( O
+PPV O
+) O
+of O
+11 O
+% O
+and O
+21 O
+% O
+for O
+term O
+infants O
+. O
+
+Including O
+the O
+five O
+missed O
+CAH O
+cases O
+identified O
+during O
+this O
+period O
+, O
+this O
+gives O
+an O
+incidence B-EPI
+of O
+1:11,200 B-STAT
+of O
+CAH O
+in O
+Sweden B-LOC
+. O
+
+Among O
+the O
+older O
+children O
+, O
+12 O
+of O
+14 O
+recalled O
+cases O
+were O
+found O
+to O
+be O
+true O
+positive O
+for O
+CAH O
+. O
+
+All O
+patients O
+were O
+genotyped O
+as O
+part O
+of O
+the O
+clinical O
+follow O
+- O
+up O
+and O
+70 O
+% O
+of O
+the O
+newborns O
+had O
+salt O
+wasting O
+( O
+SW O
+) O
+CAH O
+and O
+92 O
+% O
+had O
+classic O
+CAH O
+( O
+i.e. O
+, O
+SW O
+and O
+simple O
+virilizing O
+( O
+SV O
+) O
+CAH O
+) O
+. O
+
+In O
+the O
+group O
+of O
+12 O
+older O
+children O
+, O
+none O
+had O
+SW O
+CAH O
+and O
+two O
+had O
+SV O
+CAH O
+. O
+
+Conclusion O
+: O
+The O
+incidence B-EPI
+of O
+classic O
+CAH O
+is O
+relatively O
+high O
+in O
+Sweden B-LOC
+. O
+
+Early O
+genetic O
+confirmation O
+with O
+CYP21A2 O
+genotyping O
+has O
+been O
+a O
+valuable O
+complement O
+to O
+the O
+analysis O
+of O
+17OHP O
+to O
+predict O
+disease O
+severity O
+, O
+make O
+treatment O
+decisions O
+and O
+for O
+the O
+follow O
+- O
+up O
+and O
+evaluation O
+of O
+the O
+screening O
+program O
+. O
+
+Background O
+Juvenile O
+idiopathic O
+arthritis O
+( O
+JIA O
+) O
+is O
+a O
+heterogeneous O
+group O
+of O
+chronic O
+arthritides O
+presenting O
+in O
+patients O
+aged O
+≤16 O
+years O
+, O
+with O
+a O
+prevalence B-EPI
+of O
+16 B-STAT
+to I-STAT
+150 I-STAT
+per I-STAT
+100,000 I-STAT
+. O
+
+Juvenile O
+osteochondritis O
+dissecans O
+( O
+OCD O
+) O
+is O
+an O
+idiopathic O
+disease O
+of O
+articular O
+cartilage O
+and O
+subchondral O
+bone O
+, O
+has O
+an O
+onset O
+age O
+of O
+10 O
+to O
+16 O
+years O
+, O
+and O
+often O
+affects O
+the O
+knee O
+, O
+with O
+a O
+prevalence B-EPI
+of O
+2 B-STAT
+to I-STAT
+18 I-STAT
+per I-STAT
+100,000 I-STAT
+. O
+
+Currently O
+, O
+there O
+are O
+few O
+studies O
+that O
+have O
+evaluated O
+the O
+relationship O
+between O
+JIA O
+and O
+OCD O
+. O
+
+Hypothesis O
+OCD O
+is O
+more O
+prevalent B-EPI
+in O
+children O
+with O
+JIA O
+, O
+and O
+when O
+diagnosed O
+in O
+such O
+patients O
+, O
+OCD O
+often O
+presents O
+at O
+an O
+advanced O
+state O
+. O
+
+Study O
+design O
+Case O
+series O
+; O
+Level O
+of O
+evidence O
+, O
+4 O
+. O
+
+Methods O
+The O
+medical O
+records O
+of O
+patients O
+with O
+diagnoses O
+of O
+both O
+JIA O
+and O
+OCD O
+treated O
+between B-DATE
+January I-DATE
+2008 I-DATE
+and I-DATE
+March I-DATE
+2019 I-DATE
+at O
+a O
+single O
+children O
+'s O
+hospital O
+were O
+retrospectively O
+reviewed O
+. O
+
+Associations O
+between O
+timing O
+of O
+diagnoses O
+, O
+number O
+and O
+types O
+of O
+corticosteroid O
+treatments O
+, O
+category O
+of O
+arthritis O
+, O
+timing O
+of O
+diagnoses O
+, O
+and O
+lesion O
+stability O
+were O
+examined O
+with O
+Spearman O
+correlation O
+coefficients O
+. O
+
+Results O
+A O
+total O
+of O
+2021 O
+patients O
+with O
+JIA O
+were O
+identified O
+, O
+20 O
+of O
+whom O
+( O
+19 O
+female B-SEX
+, O
+1 O
+male B-SEX
+) O
+had O
+OCD O
+of O
+the O
+knee O
+and/or O
+talus O
+for O
+a O
+prevalence B-EPI
+of O
+1 B-STAT
+in I-STAT
+100 I-STAT
+or I-STAT
+1000 I-STAT
+in I-STAT
+100,000 I-STAT
+, O
+or O
+approximately O
+50 I-STAT
+to I-STAT
+500 I-STAT
+times I-STAT
+that I-STAT
+of O
+the O
+general O
+population O
+. O
+
+These O
+20 O
+patients O
+had O
+a O
+total O
+of O
+28 O
+OCD O
+lesions O
+: O
+43 O
+% O
+( O
+9 O
+femur O
+, O
+3 O
+talus O
+) O
+were O
+radiographically O
+stable O
+over O
+time O
+, O
+50 O
+% O
+( O
+10 O
+femur O
+, O
+2 O
+patella O
+, O
+2 O
+talus O
+) O
+were O
+unstable O
+at O
+initial O
+diagnosis O
+, O
+and O
+7 O
+% O
+( O
+2 O
+femur O
+) O
+were O
+initially O
+stable O
+but O
+progressed O
+to O
+unstable O
+lesions O
+despite O
+drilling O
+. O
+
+Twelve O
+patients O
+( O
+60 O
+% O
+) O
+underwent O
+surgery O
+: O
+4 O
+( O
+20 O
+% O
+) O
+with O
+stable O
+femoral O
+lesions O
+for O
+persistent O
+symptoms O
+despite O
+prolonged O
+nonoperative O
+treatment O
+and O
+8 O
+( O
+40 O
+% O
+) O
+for O
+treatment O
+of O
+their O
+unstable O
+lesions O
+( O
+femoral O
+and O
+patellar O
+) O
+. O
+
+Within O
+our O
+study O
+design O
+, O
+we O
+could O
+identify O
+no O
+significant O
+associations O
+between O
+lesion O
+stability O
+and O
+timing O
+of O
+diagnoses O
+, O
+number O
+of O
+joint O
+injections O
+, O
+or O
+limb O
+deformities O
+, O
+nor O
+were O
+there O
+associations O
+between O
+timing O
+of O
+JIA O
+and O
+OCD O
+diagnoses O
+and O
+category O
+of O
+arthritis O
+. O
+
+Conclusion O
+In O
+our O
+population O
+of O
+patients O
+with O
+JIA O
+, O
+OCD O
+lesions O
+were O
+found O
+to O
+be O
+50 O
+to O
+500 O
+times O
+more O
+prevalent B-EPI
+when O
+compared O
+with O
+published O
+rates O
+in O
+the O
+general O
+population O
+and O
+often O
+presented O
+at O
+an O
+advanced O
+state O
+, O
+with O
+instability O
+or O
+delayed O
+healing O
+requiring O
+surgery O
+for O
+stabilization O
+or O
+resolution O
+of O
+symptoms O
+. O
+
+Background O
+Insight O
+into O
+type O
+6 O
+long O
+- O
+QT O
+syndrome O
+( O
+LQT6 O
+) O
+, O
+stemming O
+from O
+mutations O
+in O
+the O
+KCNE2 O
+-encoded O
+voltage O
+- O
+gated O
+channel O
+β0 O
+- O
+subunit O
+, O
+is O
+limited O
+. O
+
+We O
+sought O
+to O
+further O
+characterize O
+its O
+clinical O
+phenotype O
+. O
+
+Methods O
+and O
+results O
+Individuals O
+with O
+reported O
+pathogenic O
+KCNE2 O
+mutations O
+identified O
+during O
+arrhythmia O
+evaluation O
+were O
+collected O
+from O
+inherited O
+arrhythmia O
+clinics O
+and O
+the O
+Rochester O
+long O
+- O
+QT O
+syndrome O
+( O
+LQTS O
+) O
+registry O
+. O
+
+Previously O
+reported O
+LQT6 O
+cases O
+were O
+identified O
+through O
+a O
+search O
+of O
+the O
+MEDLINE O
+database O
+. O
+
+Clinical O
+features O
+were O
+assessed O
+, O
+while O
+reported O
+KCNE2 O
+mutations O
+were O
+evaluated O
+for O
+genotype O
+- O
+phenotype O
+segregation O
+and O
+classified O
+according O
+to O
+the O
+contemporary O
+American B-ETHN
+College O
+of O
+Medical O
+Genetics O
+guidelines O
+. O
+
+Twenty O
+- O
+seven O
+probands O
+possessed O
+reported O
+pathogenic O
+KCNE2 O
+mutations O
+, O
+while O
+a O
+MEDLINE O
+search O
+identified O
+17 O
+additional O
+LQT6 O
+cases O
+providing O
+clinical O
+and O
+genetic O
+data O
+. O
+
+Sixteen O
+probands O
+had O
+normal O
+resting O
+QTc O
+values O
+and O
+only O
+developed O
+QT O
+prolongation O
+and O
+malignant O
+arrhythmias O
+after O
+exposure O
+to O
+QT O
+- O
+prolonging O
+stressors O
+, O
+10 O
+had O
+other O
+LQTS O
+pathogenic O
+mutations O
+, O
+and O
+10 O
+did O
+not O
+have O
+an O
+LQTS O
+phenotype O
+. O
+
+Although O
+the O
+remaining O
+8 O
+subjects O
+had O
+an O
+LQTS O
+phenotype O
+, O
+evidence O
+suggested O
+that O
+the O
+KCNE2 O
+variant O
+was O
+not O
+the O
+underlying O
+culprit O
+. O
+
+The O
+collective O
+frequency O
+of O
+KCNE2 O
+variants O
+implicated O
+in O
+LQT6 O
+in O
+the O
+Exome O
+Aggregation O
+Consortium O
+database O
+was O
+1.4 O
+% O
+, O
+in O
+comparison O
+with O
+a O
+0.0005 O
+% O
+estimated O
+clinical O
+prevalence I-EPI
+for O
+LQT6 O
+. O
+
+Conclusions O
+On O
+the O
+basis O
+of O
+clinical O
+phenotype O
+, O
+the O
+high O
+allelic O
+frequencies O
+of O
+LQT6 O
+mutations O
+in O
+the O
+Exome O
+Aggregation O
+Consortium O
+database O
+, O
+and O
+absence O
+of O
+previous O
+documentation O
+of O
+genotype O
+- O
+phenotype O
+segregation O
+, O
+our O
+findings O
+suggest O
+that O
+many O
+KCNE2 O
+variants O
+, O
+and O
+perhaps O
+all O
+, O
+have O
+been O
+erroneously O
+designated O
+as O
+LQTS O
+- O
+causative O
+mutations O
+. O
+
+Instead O
+, O
+KCNE2 O
+variants O
+may O
+confer O
+proarrhythmic O
+susceptibility O
+when O
+provoked O
+by O
+additional O
+environmental O
+/ O
+acquired O
+or O
+genetic O
+factors O
+, O
+or O
+both O
+. O
+
+Purpose O
+To O
+compare O
+clinical O
+outcomes O
+between O
+pars O
+plana O
+vitrectomy O
+( O
+PPV O
+) O
+, O
+scleral O
+buckling O
+( O
+SB O
+) O
+, O
+and O
+PPV+SB O
+for O
+rhegmatogenous O
+retinal O
+detachment O
+in O
+the O
+Japan O
+- O
+RD O
+Registry O
+. O
+
+Methods O
+This O
+is O
+a O
+nation O
+- O
+wide O
+, O
+multicenter O
+, O
+observational O
+study O
+based O
+on O
+the O
+registry O
+data O
+between B-DATE
+2016 I-DATE
+and I-DATE
+2017 I-DATE
+. O
+
+The O
+failure O
+levels O
+were O
+defined O
+as O
+Level O
+1 O
+( O
+a O
+failure O
+of O
+retinal O
+detachment O
+repair O
+) O
+, O
+Level O
+2 O
+( O
+remaining O
+silicone O
+oil O
+) O
+, O
+and O
+Level O
+3 O
+( O
+multiple O
+surgeries O
+to O
+achieve O
+reattachment O
+) O
+. O
+
+We O
+compared O
+cases O
+treated O
+by O
+SB O
+or O
+PPV O
+in O
+the O
+subgroup O
+of O
+simple O
+rhegmatogenous O
+retinal O
+detachment O
+using O
+multivariate O
+Cox O
+proportional O
+hazard O
+models O
+. O
+
+Results O
+A O
+total O
+of O
+2,775 O
+cases O
+were O
+included O
+. O
+
+Overall O
+, O
+6 O
+months O
+any O
+levels O
+of O
+failure O
+in O
+total O
+, O
+SB O
+, O
+PPV O
+, O
+and O
+PPV+SB O
+were O
+9.2 O
+% O
+( O
+n O
+= O
+256 O
+) O
+, O
+6.9 O
+% O
+( O
+n O
+= O
+48 O
+) O
+, O
+8.2 O
+% O
+( O
+n O
+= O
+157 O
+) O
+, O
+and O
+21.3 O
+% O
+( O
+n O
+= O
+51 O
+) O
+, O
+respectively O
+. O
+
+Poor O
+visual O
+acuity O
+at O
+baseline O
+in O
+SB O
+and O
+inferior O
+rhegmatogenous O
+retinal O
+detachment O
+and O
+larger O
+retinal O
+tear O
+in O
+PPV O
+were O
+associated O
+with O
+a O
+higher O
+risk O
+of O
+failure O
+. O
+
+Pars O
+plana O
+vitrectomy O
+was O
+associated O
+with O
+a O
+higher O
+chance O
+of O
+achieving O
+primary O
+success O
+in O
+cases O
+with O
+simple O
+RRD O
+, O
+especially O
+for O
+cases O
+with O
+superior O
+RRD O
+( O
+adjusted O
+hazard O
+ratio O
+3.61 O
+, O
+95 O
+% O
+confidence O
+interval O
+2.22 O
+- O
+5.94 O
+, O
+P O
+< O
+0.001 O
+) O
+. O
+
+Conclusion O
+In O
+this O
+nationwide O
+study O
+, O
+surgical O
+anatomic O
+outcomes O
+were O
+equally O
+successful O
+in O
+either O
+SB O
+or O
+PPV O
+. O
+
+There O
+were O
+different O
+baseline O
+characteristics O
+associated O
+with O
+primary O
+success O
+between O
+SB O
+and O
+PPV O
+. O
+
+Uveal O
+melanoma O
+( O
+UM O
+) O
+represents O
+the O
+most O
+prominent O
+primary O
+eye O
+cancer O
+in O
+adults O
+. O
+
+With O
+an O
+incidence B-EPI
+of O
+approximately B-STAT
+5 B-STAT
+cases I-STAT
+per I-STAT
+million I-STAT
+individuals I-STAT
+annually I-STAT
+in O
+the B-LOC
+United I-LOC
+States I-LOC
+, O
+UM O
+could O
+be O
+considered O
+a O
+relatively O
+rare O
+cancer O
+. O
+
+The O
+90-95 O
+% O
+of O
+UM O
+cases O
+arise O
+from O
+the O
+choroid O
+. O
+
+Diagnosis O
+is O
+based O
+mainly O
+on O
+a O
+clinical O
+examination O
+and O
+ancillary O
+tests O
+, O
+with O
+ocular O
+ultrasonography O
+being O
+of O
+greatest O
+value O
+. O
+
+Differential O
+diagnosis O
+can O
+prove O
+challenging O
+in O
+the O
+case O
+of O
+indeterminate O
+choroidal O
+lesions O
+and O
+, O
+sometimes O
+, O
+monitoring O
+for O
+documented O
+growth O
+may O
+be O
+the O
+proper O
+approach O
+. O
+
+Fine O
+needle O
+aspiration O
+biopsy O
+tends O
+to O
+be O
+performed O
+with O
+a O
+prognostic O
+purpose O
+, O
+often O
+in O
+combination O
+with O
+radiotherapy O
+. O
+
+Gene O
+expression O
+profiling O
+has O
+allowed O
+for O
+the O
+grading O
+of O
+UMs O
+into O
+two O
+classes O
+, O
+which O
+feature O
+different O
+metastatic O
+risks O
+. O
+
+Patients O
+with O
+UM O
+require O
+a O
+specialized O
+multidisciplinary O
+management O
+. O
+
+Primary O
+tumor O
+treatment O
+can O
+be O
+either O
+enucleation O
+or O
+globe O
+preserving O
+. O
+
+Usually O
+, O
+enucleation O
+is O
+reserved O
+for O
+larger O
+tumors O
+, O
+while O
+radiotherapy O
+is O
+preferred O
+for O
+small O
+/ O
+medium O
+melanomas O
+. O
+
+The O
+prognosis O
+is O
+unfavorable O
+due O
+to O
+the O
+high O
+mortality O
+rate O
+and O
+high O
+tendency O
+to O
+metastasize O
+. O
+
+Following O
+the O
+development O
+of O
+metastatic O
+disease O
+, O
+the O
+mortality O
+rate O
+increases O
+to O
+80 O
+% O
+within O
+one O
+year O
+, O
+due O
+to O
+both O
+the O
+absence O
+of O
+an O
+effective O
+treatment O
+and O
+the O
+aggressiveness O
+of O
+the O
+condition O
+. O
+
+Novel O
+molecular O
+studies O
+have O
+allowed O
+for O
+a O
+better O
+understanding O
+of O
+the O
+genetic O
+and O
+epigenetic O
+mechanisms O
+involved O
+in O
+UM O
+biological O
+activity O
+, O
+which O
+differs O
+compared O
+to O
+skin O
+melanomas O
+. O
+
+The O
+most O
+commonly O
+mutated O
+genes O
+are O
+GNAQ O
+, O
+GNA11 O
+and O
+BAP1 O
+. O
+
+Research O
+in O
+this O
+field O
+could O
+help O
+to O
+identify O
+effective O
+diagnostic O
+and O
+prognostic O
+biomarkers O
+, O
+as O
+well O
+as O
+novel O
+therapeutic O
+targets O
+. O
+
+Marine O
+mammals O
+are O
+important O
+sources O
+of O
+food O
+for O
+indigenous O
+residents O
+of O
+northern B-LOC
+Alaska I-LOC
+. O
+
+Changing O
+sea O
+ice O
+patterns O
+affect O
+the O
+animals O
+themselves O
+as O
+well O
+as O
+access O
+to O
+them O
+by O
+hunters O
+. O
+
+Documenting O
+the O
+traditional O
+knowledge O
+of O
+Iñupiaq B-ETHN
+and O
+Yupik B-ETHN
+hunters O
+concerning O
+marine O
+mammals O
+and O
+sea O
+ice O
+makes O
+accessible O
+a O
+wide O
+range O
+of O
+information O
+relevant O
+to O
+understanding O
+the O
+ecosystem O
+to O
+which O
+humans O
+belong O
+. O
+
+We O
+interviewed O
+hunters O
+in O
+11 O
+coastal O
+villages O
+from O
+the B-LOC
+northern B-LOC
+Bering I-LOC
+Sea I-LOC
+to O
+the B-LOC
+Beaufort I-LOC
+Sea I-LOC
+. O
+
+Hunters O
+reported O
+extensive O
+changes O
+in O
+sea O
+ice O
+and O
+weather O
+that O
+have O
+affected O
+the O
+timing O
+of O
+marine O
+mammal O
+migrations O
+, O
+their O
+distribution O
+and O
+behaviour O
+and O
+the O
+efficacy O
+of O
+certain O
+hunting O
+methods O
+. O
+
+Amidst O
+these O
+changes O
+, O
+however O
+, O
+hunters O
+cited O
+offsetting O
+technological O
+benefits O
+, O
+such O
+as O
+more O
+powerful O
+and O
+fuel O
+- O
+efficient O
+outboard O
+engines O
+. O
+
+Other O
+concerns O
+included O
+potential O
+impacts O
+to O
+subsistence O
+hunting O
+from O
+industrial O
+activity O
+such O
+as O
+shipping O
+and O
+oil O
+and O
+gas O
+development O
+. O
+
+While O
+hunters O
+have O
+been O
+able O
+to O
+adjust O
+to O
+some O
+changes O
+, O
+continued O
+environmental O
+changes O
+and O
+increased O
+disturbance O
+from O
+human O
+activity O
+may O
+further O
+challenge O
+their O
+ability O
+to O
+acquire O
+food O
+in O
+the O
+future O
+. O
+
+There O
+are O
+indications O
+, O
+however O
+, O
+that O
+innovation O
+and O
+flexibility O
+provide O
+sources O
+of O
+resilience O
+. O
+
+The O
+field O
+of O
+gene O
+therapy O
+is O
+striving O
+more O
+than O
+ever O
+to O
+define O
+a O
+path O
+to O
+the O
+clinic O
+and O
+the O
+market O
+. O
+
+Twenty O
+gene O
+therapy O
+products O
+have O
+already O
+been O
+approved O
+and O
+over O
+two O
+thousand O
+human O
+gene O
+therapy O
+clinical O
+trials O
+have O
+been O
+reported O
+worldwide B-LOC
+. O
+
+These O
+advances O
+raise O
+great O
+hope O
+to O
+treat O
+devastating O
+rare O
+and O
+inherited O
+diseases O
+as O
+well O
+as O
+incurable O
+illnesses O
+. O
+
+Understanding O
+of O
+the O
+precise O
+pathomechanisms O
+of O
+diseases O
+as O
+well O
+as O
+the O
+development O
+of O
+efficient O
+and O
+specific O
+gene O
+targeting O
+and O
+delivery O
+tools O
+are O
+revolutionizing O
+the O
+global O
+market O
+. O
+
+Currently O
+, O
+human O
+cancers O
+and O
+monogenic O
+disorders O
+are O
+indications O
+number O
+one O
+. O
+
+The O
+elevated O
+prevalence B-EPI
+of O
+genetic O
+disorders O
+and O
+cancers O
+, O
+clear O
+gene O
+manipulation O
+guidelines O
+and O
+increasing O
+financial O
+support O
+for O
+gene O
+therapy O
+in O
+clinical O
+trials O
+are O
+major O
+trends O
+. O
+
+Gene O
+therapy O
+is O
+presently O
+starting O
+to O
+become O
+commercially O
+profitable O
+as O
+a O
+number O
+of O
+gene O
+and O
+cell O
+- O
+based O
+gene O
+therapy O
+products O
+have O
+entered O
+the O
+market O
+and O
+the O
+clinic O
+. O
+
+This O
+article O
+reviews O
+the O
+history O
+and O
+development O
+of O
+twenty O
+approved O
+human O
+gene O
+and O
+cell O
+- O
+based O
+gene O
+therapy O
+products O
+that O
+have O
+been O
+approved O
+up O
+- O
+to O
+- O
+now O
+in O
+clinic O
+and O
+markets O
+of O
+mainly O
+North B-LOC
+America I-LOC
+, O
+Europe B-LOC
+and O
+Asia B-LOC
+. O
+
+The O
+term O
+NBIA O
+encompasses O
+a O
+heterogeneous O
+group O
+of O
+inherited O
+disorders O
+characterized O
+clinically O
+by O
+progressive O
+extra O
+pyramidal O
+syndrome O
+and O
+pathologically O
+by O
+excessive O
+iron O
+deposition O
+in O
+brain O
+, O
+primarily O
+affecting O
+the O
+basal O
+ganglia O
+( O
+globus O
+pallidus O
+mainly O
+) O
+. O
+
+The O
+hallmark O
+of O
+this O
+syndrome O
+is O
+the O
+age O
+specific O
+phenotypic O
+presentation O
+and O
+intraphenotypic O
+heterogeneity O
+. O
+
+NBIAs O
+at O
+present O
+include O
+ten O
+subtypes O
+with O
+genes O
+identified O
+in O
+nine O
+subtypes O
+. O
+
+They O
+form O
+an O
+important O
+differential O
+diagnosis O
+for O
+the O
+phenotype O
+of O
+global O
+developmental O
+delay O
+in O
+infancy O
+/ O
+childhood O
+to O
+dystonia O
+- O
+parkinsonism O
+or O
+isolated O
+parkinsonism O
+at O
+all O
+ages O
+and O
+also O
+for O
+the O
+isolated O
+craniocervical O
+dystonia O
+of O
+adult O
+onset O
+. O
+
+There O
+needs O
+to O
+be O
+a O
+high O
+index O
+of O
+clinical O
+suspicion O
+for O
+this O
+syndrome O
+and O
+the O
+evaluation O
+includes O
+MRI O
+brain O
+T2 O
+* O
+weighted O
+imaging O
+which O
+reveal O
+symmetrical O
+iron O
+deposition O
+in O
+bilateral O
+globus O
+pallidi O
+and O
+other O
+basal O
+ganglia O
+. O
+
+The O
+T2 O
+* O
+imaging O
+pattern O
+of O
+iron O
+deposition O
+varies O
+amongst O
+the O
+different O
+subtypes O
+and O
+the O
+combination O
+of O
+clinical O
+phenotype O
+and O
+MRI O
+signature O
+makes O
+it O
+easier O
+to O
+confidently O
+make O
+a O
+diagnosis O
+of O
+NBIA O
+and O
+to O
+recommend O
+genetic O
+testing O
+. O
+
+The O
+treatment O
+to O
+date O
+is O
+mostly O
+symptomatic O
+with O
+targeted O
+therapies O
+on O
+the O
+horizon O
+. O
+
+Adenylosuccinate O
+lyase O
+ADSL O
+) O
+deficiency O
+is O
+a O
+defect O
+of O
+purine O
+metabolism O
+affecting O
+purinosome O
+assembly O
+and O
+reducing O
+metabolite O
+fluxes O
+through O
+purine O
+de O
+novo O
+synthesis O
+and O
+purine O
+nucleotide O
+recycling O
+pathways O
+. O
+
+Biochemically O
+this O
+defect O
+manifests O
+by O
+the O
+presence O
+in O
+the O
+biologic O
+fluids O
+of O
+two O
+dephosphorylated O
+substrates O
+of O
+ADSL O
+enzyme O
+: O
+succinylaminoimidazole O
+carboxamide O
+riboside O
+( O
+SAICAr O
+) O
+and O
+succinyladenosine O
+( O
+S O
+- O
+Ado O
+) O
+. O
+
+More O
+than O
+80 O
+individuals O
+with O
+ADSL O
+deficiency O
+have O
+been O
+identified O
+, O
+but O
+incidence B-EPI
+of O
+the O
+disease O
+remains O
+unknown B-STAT
+. O
+
+The O
+disorder O
+shows O
+a O
+wide O
+spectrum O
+of O
+symptoms O
+from O
+slowly O
+to O
+rapidly O
+progressing O
+forms O
+. O
+
+The O
+fatal O
+neonatal O
+form O
+has O
+onset O
+from O
+birth O
+and O
+presents O
+with O
+fatal O
+neonatal O
+encephalopathy O
+with O
+a O
+lack O
+of O
+spontaneous O
+movement O
+, O
+respiratory O
+failure O
+, O
+and O
+intractable O
+seizures O
+resulting O
+in O
+early O
+death O
+within O
+the O
+first O
+weeks O
+of O
+life O
+. O
+
+Patients O
+with O
+type O
+I O
+( O
+severe O
+form O
+) O
+present O
+with O
+a O
+purely O
+neurologic O
+clinical O
+picture O
+characterized O
+by O
+severe O
+psychomotor O
+retardation O
+, O
+microcephaly O
+, O
+early O
+onset O
+of O
+seizures O
+, O
+and O
+autistic O
+features O
+. O
+
+A O
+more O
+slowly O
+progressing O
+form O
+has O
+also O
+been O
+described O
+( O
+type O
+II O
+, O
+moderate O
+or O
+mild O
+form O
+) O
+, O
+as O
+having O
+later O
+onset O
+, O
+usually O
+within O
+the O
+first O
+years O
+of O
+life O
+, O
+slight O
+to O
+moderate O
+psychomotor O
+retardation O
+and O
+transient O
+contact O
+disturbances O
+. O
+
+Diagnosis O
+is O
+facilitated O
+by O
+demonstration O
+of O
+SAICAr O
+and O
+S O
+- O
+Ado O
+in O
+extracellular O
+fluids O
+such O
+as O
+plasma O
+, O
+cerebrospinal O
+fluid O
+and/or O
+followed O
+by O
+genomic O
+and/or O
+cDNA O
+sequencing O
+and O
+characterization O
+of O
+mutant O
+proteins O
+. O
+
+Over O
+50 O
+ADSL O
+mutations O
+have O
+been O
+identified O
+and O
+their O
+effects O
+on O
+protein O
+biogenesis O
+, O
+structural O
+stability O
+and O
+activity O
+as O
+well O
+as O
+on O
+purinosome O
+assembly O
+were O
+characterized O
+. O
+
+To O
+date O
+there O
+is O
+no O
+specific O
+and O
+effective O
+therapy O
+for O
+ADSL O
+deficiency O
+. O
+
+Importance O
+Although O
+several O
+single O
+- O
+center O
+studies O
+have O
+estimated O
+that O
+granuloma O
+annulare O
+may O
+account O
+for O
+approximately O
+0.1 B-STAT
+% I-STAT
+to I-STAT
+0.4 I-STAT
+% I-STAT
+of O
+new O
+patients O
+presenting O
+to O
+dermatologists O
+, O
+large O
+- O
+scale O
+population O
+- O
+based O
+studies O
+estimating O
+the O
+prevalence B-EPI
+and O
+incidence B-EPI
+of O
+granuloma O
+annulare O
+are O
+lacking O
+. O
+
+Objectives O
+To O
+estimate O
+the O
+population O
+- O
+based I-EPI
+incidence B-EPI
+and O
+prevalence B-EPI
+of O
+granuloma O
+annulare O
+in O
+the B-LOC
+United I-LOC
+States I-LOC
+and O
+to O
+identify O
+the O
+most O
+commonly O
+prescribed O
+treatments O
+. O
+
+Design O
+, O
+setting O
+, O
+and O
+participants O
+This O
+cross O
+- O
+sectional O
+study O
+used O
+deidentified O
+data O
+from O
+the O
+Optum O
+Clinformatics O
+Data O
+Mart O
+Database O
+from O
+January B-DATE
+1 I-DATE
+, I-DATE
+2017 I-DATE
+, I-DATE
+to I-DATE
+December I-DATE
+31 I-DATE
+, I-DATE
+2018 I-DATE
+, O
+to O
+identify O
+patients O
+with O
+granuloma O
+annulare O
+. O
+
+Main O
+outcomes O
+and O
+measures O
+After O
+validating O
+an O
+approach O
+to O
+classify O
+patients O
+with O
+granuloma O
+annulare O
+using O
+International O
+Statistical O
+Classification O
+of O
+Diseases O
+and O
+Related O
+Health O
+Problems O
+, O
+Tenth O
+Revision O
+codes O
+, O
+the O
+primary O
+outcomes O
+were O
+age- O
+, O
+sex- O
+, O
+and O
+race O
+/ O
+ethnicity O
+- O
+specific O
+annualized B-EPI
+incidence I-EPI
+and O
+prevalence B-EPI
+estimates I-EPI
+for O
+granuloma O
+annulare O
+. O
+
+In O
+addition O
+, O
+treatment O
+use O
+within O
+6 O
+to O
+12 O
+months O
+after O
+the O
+first O
+diagnosis O
+of O
+granuloma O
+annulare O
+was O
+examined O
+. O
+
+Confidence O
+intervals O
+for O
+prevalence B-EPI
+and O
+incidence B-EPI
+estimates I-EPI
+were O
+computed O
+assuming O
+a O
+binomial O
+distribution O
+using O
+the O
+Wilson O
+score O
+method O
+. O
+
+Age- O
+, O
+sex- O
+, O
+and O
+race O
+/ O
+ethnicity O
+- O
+specific O
+incidence B-EPI
+and O
+prevalence B-EPI
+estimates I-EPI
+were O
+compared O
+using O
+the O
+χ2 O
+test O
+. O
+
+Results O
+A O
+total O
+of O
+11 O
+608 O
+patients O
+with O
+incident O
+granuloma O
+annulare O
+( O
+8680 O
+female B-SEX
+patients O
+[ O
+74.8 O
+% O
+] O
+; O
+mean O
+[ O
+SD O
+] O
+age O
+, O
+56.5 O
+[ O
+18.8 O
+] O
+years O
+) O
+and O
+17 O
+862 O
+patients O
+with O
+prevalent B-EPI
+granuloma O
+annulare O
+( O
+13 O
+548 O
+female B-SEX
+patients O
+[ O
+75.8 O
+% O
+] O
+; O
+mean O
+[ O
+SD O
+] O
+age O
+, O
+56.6 O
+[ O
+18.5 O
+] O
+years O
+) O
+were O
+identified O
+during O
+the O
+study O
+period O
+. O
+
+The O
+overall B-EPI
+annualized I-EPI
+incidence I-EPI
+of O
+granuloma O
+annulare O
+was O
+0.04 B-STAT
+% I-STAT
+, O
+or O
+37.9 B-STAT
+( O
+95 O
+% O
+CI O
+, O
+36.9 O
+- O
+38.9 O
+) O
+per I-STAT
+100000.0 I-STAT
+, O
+and O
+the O
+overall B-EPI
+annualized I-EPI
+prevalence I-EPI
+of O
+granuloma O
+annulare O
+was O
+0.06 B-STAT
+% I-STAT
+, O
+or O
+58.3 B-STAT
+( O
+95 O
+% O
+CI O
+, O
+57.1 O
+- O
+59.5 O
+) O
+per I-STAT
+100000.0 I-STAT
+. O
+
+The O
+incidence B-EPI
+and O
+prevalence B-EPI
+of O
+granuloma O
+annulare O
+were O
+highest O
+in O
+the O
+fifth O
+decade O
+of O
+life O
+. O
+
+The O
+incidence B-EPI
+and O
+prevalence B-EPI
+of O
+granuloma O
+annulare O
+were O
+higher O
+among O
+women B-SEX
+( O
+incidence B-EPI
+: O
+female B-SEX
+to O
+male B-SEX
+ratio O
+, O
+2.8:1 O
+; O
+prevalence B-EPI
+: O
+female B-SEX
+to O
+male B-SEX
+ratio O
+, O
+3.0:1 B-STAT
+) O
+. O
+
+Within O
+6 O
+months O
+of O
+their O
+first O
+diagnosis O
+, O
+4822 O
+patients O
+( O
+41.5 O
+% O
+) O
+filled O
+a O
+prescription O
+for O
+a O
+topical O
+corticosteroid O
+, O
+and O
+1087 O
+patients O
+( O
+9.4 O
+% O
+) O
+received O
+an O
+intralesional O
+injection O
+. O
+
+Within O
+6 O
+months O
+of O
+their O
+first O
+diagnosis O
+, O
+oral O
+tetracycline O
+prescriptions O
+were O
+filled O
+by O
+820 O
+patients O
+( O
+7.1 O
+% O
+) O
+, O
+and O
+hydroxychloroquine O
+prescriptions O
+were O
+filled O
+by O
+268 O
+patients O
+( O
+2.3 O
+% O
+) O
+. O
+
+Conclusions O
+and O
+relevance O
+Granuloma O
+annulare O
+is O
+a O
+rare O
+disease O
+in O
+the B-LOC
+United I-LOC
+States I-LOC
+that O
+is O
+more O
+common O
+among O
+women B-SEX
+and O
+middle O
+- O
+aged O
+to O
+older O
+individuals O
+. O
+
+The O
+findings O
+of O
+this O
+cross O
+- O
+sectional O
+study O
+provide O
+important O
+background O
+regarding O
+the O
+basic O
+epidemiology O
+and O
+overall O
+burden O
+of O
+granuloma O
+annulare O
+in O
+the B-LOC
+United I-LOC
+States I-LOC
+. O
+
+Future O
+studies O
+are O
+needed O
+to O
+better O
+understand O
+the O
+association O
+of O
+granuloma O
+annulare O
+with O
+quality O
+of O
+life O
+and O
+the O
+most O
+optimal O
+treatment O
+approaches O
+for O
+this O
+condition O
+. O
+
+Purpose O
+We O
+investigated O
+the O
+prevalence B-EPI
+of O
+Modic O
+changes O
+( O
+MCs O
+) O
+and O
+associated O
+pathologies O
+in O
+pediatric O
+patients O
+. O
+
+Methods O
+A O
+total O
+of O
+368 O
+MRI O
+obtained O
+for O
+240 O
+male B-SEX
+and O
+128 O
+female B-SEX
+patients O
+under O
+the O
+age O
+of O
+18 O
+years O
+with O
+complaints O
+of O
+low O
+back O
+/ O
+leg O
+pain O
+were O
+retrospectively O
+examined O
+. O
+
+All O
+changes O
+in O
+signal O
+intensity O
+in O
+the O
+vertebral O
+endplate O
+and O
+subchondral O
+bone O
+on O
+MRI O
+were O
+defined O
+as O
+MCs O
+. O
+
+We O
+investigated O
+the O
+relationship O
+between O
+MCs O
+and O
+underlying O
+diseases O
+, O
+including O
+lumbar O
+spondylolysis O
+/ O
+spondylolisthesis O
+, O
+and O
+conditions O
+of O
+the O
+growth O
+plate O
+in O
+cases O
+with O
+MCs O
+. O
+
+The O
+degree O
+of O
+disc O
+degeneration O
+in O
+patients O
+with O
+MCs O
+was O
+evaluated O
+using O
+the O
+Pfirrmann O
+grading O
+system O
+. O
+
+Results O
+MCs O
+were O
+identified O
+in O
+six O
+patients O
+( O
+1.6 O
+% O
+) O
+. O
+
+In O
+five O
+of O
+the O
+six O
+patients O
+, O
+the O
+signal O
+intensity O
+changes O
+were O
+localized O
+to O
+the O
+anterosuperior O
+endplate O
+of O
+the O
+affected O
+vertebra O
+; O
+the O
+MCs O
+were O
+associated O
+with O
+anterior O
+apophyseal O
+ring O
+fracture O
+and O
+an O
+open O
+growth O
+plate O
+in O
+all O
+these O
+cases O
+. O
+
+Disc O
+degeneration O
+was O
+classified O
+as O
+Pfirrmann O
+grade O
+I O
+in O
+three O
+patients O
+and O
+grade O
+II O
+and O
+III O
+in O
+one O
+patient O
+each O
+. O
+
+One O
+patient O
+had O
+type O
+I O
+changes O
+associated O
+with O
+grade O
+IV O
+disc O
+degeneration O
+and O
+herniation O
+and O
+no O
+sign O
+of O
+an O
+open O
+growth O
+plate O
+. O
+
+Conclusion O
+The O
+prevalence B-EPI
+of O
+MCs O
+in O
+pediatrics O
+patients O
+was O
+much O
+lower O
+than O
+the O
+rates O
+reported O
+in O
+adults O
+. O
+
+Most O
+MCs O
+were O
+associated O
+with O
+an O
+anterior O
+apophyseal O
+ring O
+fracture O
+. O
+
+If O
+Modic O
+type O
+changes O
+are O
+seen O
+in O
+immature O
+vertebrae O
+of O
+pediatric O
+patients O
+, O
+growth O
+plate O
+lesions O
+such O
+as O
+apophyseal O
+ring O
+fractures O
+should O
+be O
+considered O
+. O
+
+Level O
+of O
+evidence O
+Diagnostic O
+: O
+individual O
+l O
+cross O
+- O
+sectional O
+studies O
+with O
+consistently O
+applied O
+reference O
+standard O
+and O
+blinding O
+. O
+
+Background O
+Ehlers O
+- O
+Danlos O
+syndrome O
+( O
+EDS O
+) O
+represents O
+a O
+group O
+of O
+connective O
+tissue O
+disorders O
+characterized O
+by O
+the O
+fragility O
+of O
+the O
+soft O
+connective O
+tissues O
+resulting O
+in O
+widespread O
+skin O
+, O
+ligament O
+, O
+joint O
+, O
+blood O
+vessel O
+and O
+internal O
+organ O
+involvement O
+. O
+
+The O
+clinical O
+spectrum O
+is O
+highly O
+variable O
+in O
+terms O
+of O
+clinical O
+features O
+, O
+complications O
+, O
+severity O
+, O
+biochemical O
+characteristics O
+and O
+genes O
+mutations O
+. O
+
+The O
+kyphoscoliotic O
+type O
+EDS O
+( O
+EDS O
+VIA O
+) O
+is O
+a O
+rare O
+variant O
+of O
+the O
+disease O
+, O
+with O
+an O
+incidence B-EPI
+of O
+1:100.000 B-STAT
+live I-STAT
+births I-STAT
+. O
+
+EDS O
+VIA O
+presents O
+at O
+birth O
+as O
+severe O
+muscular O
+hypotonia O
+, O
+early O
+onset O
+of O
+progressive O
+kyphoscoliosis O
+, O
+marked O
+hyperelasticity O
+and O
+fragility O
+of O
+the O
+skin O
+with O
+abnormal O
+scarring O
+, O
+severe O
+joint O
+hypermobility O
+, O
+luxations O
+and O
+osteopenia O
+without O
+a O
+tendency O
+to O
+fractures O
+. O
+
+This O
+condition O
+is O
+due O
+to O
+a O
+mutation O
+in O
+the O
+PLOD1 O
+gene O
+, O
+and O
+less O
+commonly O
+in O
+FKBP14 O
+gene O
+, O
+which O
+results O
+in O
+the O
+erroneous O
+development O
+of O
+collagen O
+molecules O
+with O
+consequent O
+mechanical O
+instability O
+of O
+the O
+affected O
+tissue O
+. O
+
+Case O
+presentation O
+A O
+female B-SEX
+newborn O
+, O
+found O
+to O
+be O
+floppy O
+at O
+birth O
+, O
+presented O
+a O
+remarkable O
+physical O
+examination O
+for O
+joint O
+hypermobility O
+, O
+muscle O
+weakness O
+, O
+hyperelastic O
+skin O
+, O
+a O
+slight O
+curve O
+of O
+the O
+spine O
+, O
+the O
+absence O
+of O
+the O
+inferior O
+labial O
+and O
+lingual O
+frenulum O
+. O
+
+Due O
+to O
+severe O
+hypotonia O
+, O
+neuromuscular O
+disorders O
+such O
+as O
+Spinal O
+Muscular O
+Atrophy O
+( O
+SMA O
+) O
+, O
+genetic O
+diseases O
+such O
+as O
+Prader O
+Willi O
+syndrome O
+( O
+PWS O
+) O
+, O
+myopathies O
+and O
+connective O
+tissue O
+disorders O
+were O
+considered O
+in O
+the O
+differential O
+diagnosis O
+. O
+
+Targeted O
+gene O
+sequencing O
+were O
+performed O
+for O
+SMN1 O
+, O
+PLOD1 O
+, O
+FKBP14 O
+, O
+COL6A1 O
+, O
+COL6A2 O
+, O
+COL6A3 O
+. O
+
+The O
+urinary O
+lysyl O
+and O
+hydroxy O
+- O
+lysyl O
+pyridinoline O
+ratio O
+was O
+diagnostic O
+before O
+discovering O
+the O
+homozygous O
+duplication O
+in O
+the O
+PLOD1 O
+gene O
+, O
+which O
+confirmed O
+kyphoscoliotic O
+EDS O
+diagnosis O
+. O
+
+Conclusion O
+In O
+front O
+of O
+a O
+floppy O
+infant O
+, O
+a O
+large O
+variety O
+of O
+disorders O
+should O
+be O
+considered O
+, O
+including O
+some O
+connective O
+diseases O
+. O
+
+The O
+presence O
+at O
+the O
+birth O
+of O
+kyphoscoliosis O
+, O
+associated O
+with O
+joint O
+hypermobility O
+and O
+the O
+absence O
+of O
+the O
+lingual O
+and O
+lower O
+lip O
+frenulum O
+, O
+should O
+suggest O
+an O
+EDS O
+. O
+
+More O
+than O
+1 I-STAT
+out I-STAT
+of I-STAT
+10 I-STAT
+women B-SEX
+worldwide B-LOC
+are O
+diagnosed O
+with O
+polycystic O
+ovary O
+syndrome O
+( O
+PCOS O
+) O
+, O
+the O
+leading O
+cause O
+of O
+female B-SEX
+reproductive O
+and O
+metabolic O
+dysfunction O
+. O
+
+Despite O
+its O
+high O
+prevalence B-EPI
+, O
+PCOS O
+and O
+its O
+accompanying O
+morbidities O
+are O
+likely O
+underdiagnosed O
+, O
+averaging O
+> O
+2 O
+years O
+and O
+3 O
+physicians O
+before O
+women B-SEX
+are O
+diagnosed O
+. O
+
+Although O
+it O
+has O
+been O
+intensively O
+researched O
+, O
+the O
+underlying O
+cause(s O
+) O
+of O
+PCOS O
+have O
+yet O
+to O
+be O
+defined O
+. O
+
+In O
+order O
+to O
+understand O
+PCOS O
+pathophysiology O
+, O
+its O
+developmental O
+origins O
+, O
+and O
+how O
+to O
+predict O
+and O
+prevent O
+PCOS O
+onset O
+, O
+there O
+is O
+an O
+urgent O
+need O
+for O
+safe O
+and O
+effective O
+markers O
+and O
+treatments O
+. O
+
+In O
+this O
+review O
+, O
+we O
+detail O
+which O
+animal O
+models O
+are O
+more O
+suitable O
+for O
+contributing O
+to O
+our O
+understanding O
+of O
+the O
+etiology O
+and O
+pathophysiology O
+of O
+PCOS O
+. O
+
+We O
+summarize O
+and O
+highlight O
+advantages O
+and O
+limitations O
+of O
+hormonal O
+or O
+genetic O
+manipulation O
+of O
+animal O
+models O
+, O
+as O
+well O
+as O
+of O
+naturally O
+occurring O
+PCOS O
+- O
+like O
+females B-SEX
+. O
+
+Anticancer O
+drug O
+nephrotoxicity O
+is O
+an O
+important O
+and O
+increasing O
+adverse O
+drug O
+event O
+that O
+limits O
+the O
+efficacy O
+of O
+cancer O
+treatment O
+. O
+
+The O
+kidney O
+is O
+an O
+important O
+elimination O
+pathway O
+for O
+many O
+antineoplastic O
+drugs O
+and O
+their O
+metabolites O
+, O
+which O
+occurs O
+by O
+glomerular O
+filtration O
+and O
+tubular O
+secretion O
+. O
+
+Chemotherapeutic O
+agents O
+, O
+both O
+conventional O
+cytotoxic O
+agents O
+and O
+molecularly O
+targeted O
+agents O
+, O
+can O
+affect O
+any O
+segment O
+of O
+the O
+nephron O
+including O
+its O
+microvasculature O
+, O
+leading O
+to O
+many O
+clinical O
+manifestations O
+such O
+as O
+proteinuria O
+, O
+hypertension O
+, O
+electrolyte O
+disturbances O
+, O
+glomerulopathy O
+, O
+acute O
+and O
+chronic O
+interstitial O
+nephritis O
+, O
+acute O
+kidney O
+injury O
+and O
+at O
+times O
+chronic O
+kidney O
+disease O
+. O
+
+The O
+clinician O
+should O
+be O
+alert O
+to O
+recognize O
+several O
+factors O
+that O
+may O
+maximize O
+renal O
+dysfunction O
+and O
+contribute O
+to O
+the O
+increased O
+incidence B-EPI
+of O
+nephrotoxicity O
+associated O
+with O
+these O
+drugs O
+, O
+such O
+as O
+intravascular O
+volume O
+depletion O
+, O
+the O
+associated O
+use O
+of O
+nonchemotherapeutic O
+nephrotoxic O
+drugs O
+( O
+analgesics O
+, O
+antibiotics O
+, O
+proton O
+pump O
+inhibitors O
+, O
+and O
+bone O
+- O
+targeted O
+therapies O
+) O
+, O
+radiographic O
+ionic O
+contrast O
+media O
+or O
+radiation O
+therapy O
+, O
+urinary O
+tract O
+obstruction O
+, O
+and O
+intrinsic O
+renal O
+disease O
+. O
+
+Identification O
+of O
+patients O
+at O
+higher O
+risk O
+for O
+nephrotoxicity O
+may O
+allow O
+the O
+prevention O
+or O
+at O
+least O
+reduction O
+in O
+the O
+development O
+and O
+severity O
+of O
+this O
+adverse O
+effect O
+. O
+
+Therefore O
+, O
+the O
+aim O
+of O
+this O
+brief O
+review O
+is O
+to O
+provide O
+currently O
+available O
+evidences O
+on O
+oncologic O
+drug O
+- O
+related O
+nephrotoxicity O
+. O
+
+Zika O
+virus O
+( O
+ZIKV O
+) O
+is O
+a O
+vectorborne O
+infectious O
+agent O
+of O
+global O
+public O
+health O
+significance O
+due O
+to O
+its O
+potential O
+to O
+cause O
+severe O
+teratogenic O
+outcomes O
+. O
+
+The O
+question O
+of O
+whether O
+health O
+systems O
+should O
+consider O
+adopting O
+screening O
+programmes O
+for O
+ZIKV O
+infections O
+during O
+pregnancy O
+warrants O
+consideration O
+. O
+
+In O
+this O
+analysis O
+, O
+we O
+apply O
+the O
+Wilson O
+- O
+Jungner O
+framework O
+to O
+appraise O
+the O
+potential O
+utility O
+of O
+a O
+prenatal O
+ZIKV O
+screening O
+programme O
+, O
+outline O
+potential O
+screening O
+strategies O
+within O
+the O
+case O
+- O
+finding O
+pathway O
+, O
+and O
+consider O
+other O
+epidemiological O
+factors O
+that O
+may O
+influence O
+the O
+planning O
+of O
+such O
+a O
+screening O
+programme O
+. O
+
+Our O
+evaluation O
+of O
+a O
+potential O
+prenatal O
+ZIKV O
+screening O
+programme O
+highlights O
+factors O
+affirming O
+its O
+usefulness O
+, O
+including O
+the O
+importance O
+of O
+Congenital O
+Zika O
+Syndrome O
+as O
+a O
+public O
+health O
+problem O
+and O
+the O
+existence O
+of O
+analogous O
+congenital O
+prenatal O
+screening O
+programmes O
+for O
+STORCH O
+agents O
+( O
+syphilis O
+, O
+toxoplasmosis O
+, O
+others O
+( O
+eg O
+, O
+human O
+immunodeficiency O
+virus O
+, O
+varicella O
+- O
+zoster O
+virus O
+, O
+parvovirus O
+B19 O
+) O
+, O
+rubella O
+, O
+cytomegalovirus O
+, O
+and O
+herpes O
+simplex O
+virus O
+) O
+. O
+
+However O
+, O
+our O
+assessment O
+also O
+reveals O
+key O
+barriers O
+to O
+implementation O
+, O
+such O
+as O
+the O
+need O
+for O
+more O
+accurate O
+diagnostic O
+tests O
+, O
+effective O
+antiviral O
+treatments O
+, O
+increased O
+social O
+service O
+capacity O
+, O
+and O
+surveillance O
+. O
+
+Given O
+that O
+the O
+reemergence O
+of O
+ZIKV O
+is O
+likely O
+, O
+we O
+provide O
+a O
+guiding O
+framework O
+for O
+policymakers O
+and O
+public O
+health O
+leaders O
+that O
+can O
+be O
+further O
+elaborated O
+and O
+adapted O
+to O
+different O
+contexts O
+in O
+order O
+to O
+reduce O
+the O
+burden O
+of O
+adverse O
+ZIKV O
+- O
+related O
+birth O
+outcomes O
+during O
+future O
+outbreaks O
+. O
+
+We O
+aimed O
+to O
+explore O
+the O
+genetic O
+and O
+environmental O
+contributions O
+to O
+variation O
+in O
+the O
+risk O
+of O
+hematologic O
+malignancies O
+and O
+characterize O
+familial O
+dependence O
+within O
+and O
+across O
+hematologic O
+malignancies O
+. O
+
+The O
+study O
+base O
+included O
+316,397 O
+individual O
+twins O
+from O
+the O
+Nordic O
+Twin O
+Study O
+of O
+Cancer O
+with O
+a O
+median O
+of O
+41 O
+years O
+of O
+follow O
+- O
+up O
+: O
+88,618 O
+( O
+28 O
+% O
+) O
+of O
+the O
+twins O
+were O
+monozygotic O
+, O
+and O
+3459 O
+hematologic O
+malignancies O
+were O
+reported O
+. O
+
+We O
+estimated O
+the O
+cumulative B-EPI
+incidence I-EPI
+by O
+age O
+, O
+familial O
+risk O
+, O
+and O
+genetic O
+and O
+environmental O
+variance O
+components O
+of O
+hematologic O
+malignancies O
+accounting O
+for O
+competing O
+risk O
+of O
+death O
+. O
+
+The O
+lifetime O
+risk O
+of O
+any O
+hematologic O
+malignancy O
+was O
+2.5 O
+% O
+( O
+95 O
+% O
+CI O
+2.4 O
+- O
+2.6 O
+% O
+) O
+, O
+as O
+in O
+the O
+background O
+population O
+. O
+
+This O
+risk O
+was O
+elevated O
+to O
+4.5 O
+% O
+( O
+95 O
+% O
+CI O
+3.1 O
+- O
+6.5 O
+% O
+) O
+conditional O
+on O
+hematologic O
+malignancy O
+in O
+a O
+dizygotic O
+co O
+- O
+twin O
+and O
+was O
+even O
+greater O
+at O
+7.6 O
+% O
+( O
+95 O
+% O
+CI O
+4.8 O
+- O
+11.8 O
+% O
+) O
+if O
+a O
+monozygotic O
+co O
+- O
+twin O
+had O
+a O
+hematologic O
+malignancy O
+. O
+
+Heritability O
+of O
+the O
+liability O
+to O
+develop O
+any O
+hematologic O
+malignancy O
+was O
+24 O
+% O
+( O
+95 O
+% O
+CI O
+14 O
+- O
+33 O
+% O
+) O
+. O
+
+This O
+estimate O
+decreased O
+across O
+age O
+, O
+from O
+approximately O
+55 O
+% O
+at O
+age O
+40 O
+to O
+about O
+20 O
+- O
+25 O
+% O
+after O
+age O
+55 O
+, O
+when O
+it O
+seems O
+to O
+stabilize O
+. O
+
+In O
+this O
+largest O
+ever O
+studied O
+twin O
+cohort O
+with O
+the O
+longest O
+follow O
+- O
+up O
+, O
+we O
+found O
+evidence O
+for O
+familial O
+risk O
+of O
+hematologic O
+malignancies O
+. O
+
+The O
+discovery O
+of O
+decreasing O
+familial O
+predisposition O
+with O
+increasing O
+age O
+underscores O
+the O
+importance O
+of O
+cancer O
+surveillance O
+in O
+families O
+with O
+hematological O
+malignancies O
+. O
+
+A O
+57 O
+- O
+year O
+- O
+old O
+male B-SEX
+presented O
+to O
+the O
+emergency O
+department O
+with O
+right O
+upper O
+quadrant O
+pain O
+and O
+constitutional O
+symptoms O
+. O
+
+Initial O
+investigation O
+revealed O
+biliary O
+sepsis O
+with O
+features O
+of O
+chronic O
+cholecystitis O
+, O
+multiple O
+liver O
+abscesses O
+and O
+a O
+fistulous O
+connection O
+between O
+the O
+gallbladder O
+and O
+colon O
+. O
+
+He O
+was O
+subsequently O
+diagnosed O
+with O
+a O
+cholecysto O
+- O
+colonic O
+fistula O
+, O
+an O
+unusual O
+complication O
+of O
+biliary O
+pathology O
+, O
+with O
+an O
+incidence B-EPI
+of O
+0.06 B-STAT
+- I-STAT
+0.14 I-STAT
+% I-STAT
+at O
+cholecystectomy O
+. O
+
+It O
+is O
+the O
+second O
+most O
+common O
+form O
+of O
+cholecystoenteric O
+fistula O
+, O
+the O
+first O
+of O
+which O
+is O
+cholecystoduodenal O
+. O
+
+A O
+preoperative O
+diagnosis O
+was O
+suggested O
+using O
+computed O
+tomography O
+and O
+sinogram O
+imaging O
+. O
+
+The O
+associated O
+liver O
+abscesses O
+together O
+with O
+the O
+xanthogranulomatous O
+inflammation O
+found O
+on O
+histopathology O
+, O
+makes O
+the O
+case O
+particularly O
+exceptional O
+. O
+
+Massachusetts B-LOC
+began O
+newborn O
+screening O
+( O
+NBS O
+) O
+for O
+Spinal O
+Muscular O
+Atrophy O
+( O
+SMA O
+) O
+following O
+the O
+availability O
+of O
+new O
+treatment O
+options O
+. O
+
+The O
+New B-LOC
+England I-LOC
+Newborn O
+Screening O
+Program O
+developed O
+, O
+validated O
+, O
+and O
+implemented O
+a O
+screening O
+algorithm O
+for O
+the O
+detection O
+of O
+SMA O
+- O
+affected O
+infants O
+who O
+show O
+absent O
+SMN1 O
+Exon O
+7 O
+by O
+Real O
+- O
+Time O
+quantitative O
+PCR O
+( O
+qPCR O
+) O
+. O
+
+We O
+screened O
+179,467 O
+neonates O
+and O
+identified O
+9 O
+SMA O
+- O
+affected O
+infants O
+, O
+all O
+of O
+whom O
+were O
+referred O
+to O
+a O
+specialist O
+by O
+day O
+of O
+life O
+6 O
+( O
+average O
+and O
+median O
+4 O
+days O
+of O
+life O
+) O
+. O
+
+Another O
+ten O
+SMN1 O
+hybrids O
+were O
+observed O
+but O
+never O
+referred O
+. O
+
+The O
+nine O
+referred O
+infants O
+who O
+were O
+confirmed O
+to O
+have O
+SMA O
+were O
+entered O
+into O
+treatment O
+protocols O
+. O
+
+Early O
+data O
+show O
+that O
+some O
+SMA O
+- O
+affected O
+children O
+have O
+remained O
+asymptomatic O
+and O
+are O
+meeting O
+developmental O
+milestones O
+and O
+some O
+have O
+mild O
+to O
+moderate O
+delays O
+. O
+
+The O
+Massachusetts B-LOC
+experience O
+demonstrates O
+that O
+SMA O
+NBS O
+is O
+feasible O
+, O
+can O
+be O
+implemented O
+on O
+a O
+population O
+basis O
+, O
+and O
+helps O
+engage O
+infants O
+for O
+early O
+treatment O
+to O
+maximize O
+benefit O
+. O
+
+This O
+study O
+aims O
+to O
+assess O
+the O
+prevalence B-EPI
+, O
+distribution O
+, O
+and O
+etiological O
+profile O
+of O
+intestinal O
+parasitism O
+in O
+children O
+living O
+in O
+periurban O
+areas O
+in O
+Cachoeiras B-LOC
+de I-LOC
+Macacu I-LOC
+, O
+Rio B-LOC
+de I-LOC
+Janeiro I-LOC
+, I-LOC
+Brazil I-LOC
+. O
+
+A O
+community O
+- O
+based O
+cross O
+- O
+sectional O
+survey O
+( O
+n O
+= O
+479 O
+) O
+was O
+carried O
+out O
+. O
+
+Prevalence B-EPI
+of O
+infection O
+with O
+G. O
+duodenalis O
+and O
+E. O
+histolytica O
+/ O
+E. O
+dispar O
+was O
+8.6 O
+% O
+( O
+n O
+= O
+41 O
+) O
+and O
+13.4 O
+% O
+( O
+n O
+= O
+64 O
+) O
+, O
+respectively O
+. O
+
+Infection O
+with O
+G. O
+duodenalis O
+was O
+significantly O
+more O
+frequent O
+among O
+children O
+living O
+in O
+poor O
+families O
+( O
+24/187 O
+( O
+12.8 O
+% O
+) O
+vs. O
+16/272 O
+( O
+5.9 O
+% O
+) O
+; O
+prevalence B-EPI
+ratio O
+( O
+PR O
+) O
+= O
+2.18 O
+; O
+95 O
+% O
+confidence O
+interval O
+( O
+CI O
+) O
+= O
+1.19 O
+- O
+3.99 O
+; O
+p O
+= O
+0.011 O
+) O
+. O
+
+This O
+difference O
+was O
+also O
+significant O
+for O
+infection O
+with O
+any O
+pathogenic O
+parasite O
+( O
+43/187 O
+( O
+23 O
+% O
+) O
+vs. O
+40/272 O
+( O
+14/7 O
+% O
+) O
+; O
+PR O
+= O
+1.56 O
+; O
+95 O
+% O
+CI O
+= O
+1.06 O
+- O
+2.30 O
+; O
+p O
+= O
+0.026 O
+) O
+. O
+
+In O
+addition O
+, O
+people O
+residing O
+in O
+houses O
+with O
+more O
+than O
+four O
+inhabitants O
+showed O
+significantly O
+higher O
+positivity O
+for O
+infections O
+with O
+G. O
+duodenalis O
+and O
+with O
+E. O
+histolytica O
+/ O
+E. O
+dispar O
+( O
+22/138 O
+( O
+15.9 O
+% O
+) O
+vs. O
+16/311 O
+( O
+5.1 O
+% O
+) O
+; O
+PR O
+= O
+3.09 O
+; O
+95 O
+% O
+CI O
+= O
+1.68 O
+- O
+5.71 O
+; O
+p O
+< O
+0.001 O
+for O
+G. O
+duodenalis O
+and O
+32/138 O
+( O
+23.2 O
+% O
+) O
+vs. O
+30/311 O
+( O
+9.6 O
+% O
+) O
+; O
+PR O
+= O
+2.40 O
+; O
+95 O
+% O
+CI O
+= O
+1.52 O
+- O
+
+3.79 O
+; O
+p O
+< O
+0.001 O
+for O
+E. O
+histolytica O
+/ O
+E. O
+dispar O
+) O
+. O
+
+Laboratory O
+diagnosis O
+of O
+protozoan O
+enteric O
+infections O
+and O
+effective O
+drugs O
+for O
+their O
+treatment O
+are O
+unmet O
+goals O
+in O
+the O
+primary O
+health O
+care O
+system O
+. O
+
+Therefore O
+, O
+giardiasis O
+and O
+amebiasis O
+are O
+neglected O
+conditions O
+. O
+
+An O
+accurate O
+diagnosis O
+of O
+syndromic O
+craniosynostosis O
+( O
+CS O
+) O
+is O
+important O
+for O
+personalized O
+treatment O
+, O
+surveillance O
+, O
+and O
+genetic O
+counselling O
+. O
+
+We O
+describe O
+detailed O
+clinical O
+criteria O
+for O
+syndromic O
+CS O
+and O
+the O
+distribution O
+of O
+genetic O
+diagnoses O
+within O
+the O
+cohort O
+. O
+
+The O
+prospective O
+registry O
+of O
+the O
+Norwegian B-ETHN
+National O
+Unit O
+for O
+Craniofacial O
+Surgery O
+was O
+used O
+to O
+retrieve O
+individuals O
+with O
+syndromic O
+CS O
+born O
+between B-DATE
+1 I-DATE
+January I-DATE
+2002 I-DATE
+and I-DATE
+30 I-DATE
+June I-DATE
+2019 I-DATE
+. O
+
+All O
+individuals O
+were O
+assessed O
+by O
+a O
+clinical O
+geneticist O
+and O
+classified O
+using O
+defined O
+clinical O
+criteria O
+. O
+
+A O
+stepwise O
+approach O
+consisting O
+of O
+single O
+- O
+gene O
+analysis O
+, O
+comparative O
+genomic O
+hybridization O
+( O
+aCGH O
+) O
+, O
+and O
+exome O
+- O
+based O
+high O
+- O
+throughput O
+sequencing O
+, O
+first O
+filtering O
+for O
+72 O
+genes O
+associated O
+with O
+syndromic O
+CS O
+, O
+followed O
+by O
+an O
+extended O
+trio O
+- O
+based O
+panel O
+of O
+1570 O
+genes O
+were O
+offered O
+to O
+all O
+syndromic O
+CS O
+cases O
+. O
+
+A O
+total O
+of O
+381 O
+individuals O
+were O
+registered O
+with O
+CS O
+, O
+of O
+whom O
+104 O
+( O
+27 O
+% O
+) O
+were O
+clinically O
+classified O
+as O
+syndromic O
+CS O
+. O
+
+Using O
+the O
+single O
+- O
+gene O
+analysis O
+, O
+aCGH O
+, O
+and O
+custom O
+- O
+designed O
+panel O
+, O
+a O
+genetic O
+diagnosis O
+was O
+confirmed O
+in O
+73 O
+% O
+of O
+the O
+individuals O
+( O
+n O
+= O
+94 O
+) O
+. O
+
+The O
+diagnostic O
+yield O
+increased O
+to O
+84 O
+% O
+after O
+adding O
+the O
+results O
+from O
+the O
+extended O
+trio O
+- O
+based O
+panel O
+. O
+
+Common O
+causes O
+of O
+syndromic O
+CS O
+were O
+found O
+in O
+53 O
+individuals O
+( O
+56 O
+% O
+) O
+, O
+whereas O
+26 O
+( O
+28 O
+% O
+) O
+had O
+other O
+genetic O
+syndromes O
+, O
+including O
+17 O
+individuals O
+with O
+syndromes O
+not O
+commonly O
+associated O
+with O
+CS O
+. O
+
+Only O
+15 O
+individuals O
+( O
+16 O
+% O
+) O
+had O
+negative O
+genetic O
+analyses O
+. O
+
+Using O
+the O
+defined O
+combination O
+of O
+clinical O
+criteria O
+, O
+we O
+detected O
+among O
+the O
+highest O
+numbers O
+of O
+syndromic O
+CS O
+cases O
+reported O
+, O
+confirmed O
+by O
+a O
+high O
+genetic O
+diagnostic O
+yield O
+of O
+84 O
+% O
+. O
+
+The O
+observed O
+genetic O
+heterogeneity O
+encourages O
+a O
+broad O
+genetic O
+approach O
+in O
+diagnosing O
+syndromic O
+CS O
+. O
+
+Background O
+National O
+neonatal O
+surveillance O
+for O
+herpes O
+simplex O
+virus O
+( O
+HSV O
+) O
+disease O
+suggests O
+that O
+the O
+incidence B-EPI
+of O
+HSV O
+disease O
+may O
+be O
+higher O
+in O
+Queensland B-LOC
+( O
+QLD B-LOC
+) O
+than O
+in O
+other O
+Australian B-LOC
+States I-LOC
+. O
+
+We O
+sought O
+to O
+investigate O
+the O
+incidence B-EPI
+via O
+a O
+retrospective O
+13 O
+- O
+year O
+evaluation O
+of O
+statewide O
+laboratory O
+data O
+, O
+autopsy O
+data O
+and O
+linked O
+clinical O
+records O
+of O
+infants O
+with O
+laboratory O
+confirmed O
+infection O
+. O
+
+Methods O
+All O
+positive O
+polymerase O
+chain O
+reaction O
+HSV O
+1 O
+and O
+2 O
+results O
+were O
+obtained O
+for O
+infants O
+0 O
+- O
+3 O
+months O
+of O
+age O
+from O
+January B-DATE
+1 I-DATE
+, I-DATE
+2005 I-DATE
+to I-DATE
+December I-DATE
+31 I-DATE
+, I-DATE
+2017 I-DATE
+. O
+
+Clinical O
+data O
+were O
+obtained O
+from O
+patient O
+records O
+and O
+parent O
+questionnaires O
+were O
+used O
+to O
+evaluate O
+long O
+- O
+term O
+sequelae O
+. O
+
+Results O
+One O
+hundred O
+seventy O
+- O
+two O
+infants O
+with O
+HSV O
+positive O
+polymerase O
+chain O
+reaction O
+results O
+: O
+121 O
+( O
+70.3 O
+% O
+) O
+with O
+HSV O
+1 O
+. O
+
+Of O
+104 O
+( O
+60.5 O
+% O
+) O
+infants O
+with O
+signs O
+of O
+HSV O
+disease O
+, O
+76 O
+( O
+73.1 O
+% O
+) O
+were O
+neonates O
+( O
+≤28 O
+days O
+of O
+age O
+) O
+[ O
+incidence B-EPI
+9.6 B-STAT
+( O
+95 O
+% O
+confidence O
+interval O
+, O
+7.0 O
+- O
+11.5 O
+) O
+per I-STAT
+100,000 I-STAT
+live I-STAT
+births I-STAT
+] O
+and O
+28 O
+( O
+26.9 O
+% O
+) O
+were O
+young O
+infants O
+( O
+29 O
+- O
+90 O
+days O
+of O
+age O
+) O
+[ O
+3.6 B-STAT
+( O
+95 O
+% O
+confidence O
+interval O
+, O
+2.4 O
+- O
+5.4 O
+) I-STAT
+per I-STAT
+100,000 I-STAT
+live I-STAT
+births I-STAT
+] O
+. O
+
+The O
+annual B-EPI
+incidence I-EPI
+of O
+neonatal O
+HSV O
+disease O
+increased O
+significantly O
+in O
+Queensland B-LOC
+over O
+the O
+study O
+period O
+( O
+P O
+< O
+0.01 O
+) O
+. O
+
+Of O
+the O
+76 O
+neonates O
+with O
+HSV O
+disease O
+, O
+58 O
+( O
+76.3 O
+% O
+) O
+presented O
+with O
+the O
+skin O
+, O
+eye O
+, O
+mouth O
+( O
+SEM O
+) O
+disease O
+, O
+17 O
+( O
+22.4 O
+% O
+) O
+with O
+HSV O
+encephalitis O
+and O
+11 O
+( O
+14.5 O
+% O
+) O
+had O
+disseminated O
+disease O
+. O
+
+Young O
+infants O
+presented O
+with O
+HSV O
+skin O
+, O
+eye O
+, O
+mouth O
+disease O
+( O
+21 O
+, O
+75.0 O
+% O
+) O
+or O
+HSV O
+encephalitis O
+( O
+6 O
+, O
+21.4 O
+% O
+) O
+. O
+
+Death O
+occurred O
+in O
+12/104 O
+( O
+11.5 O
+% O
+) O
+infants O
+( O
+all O
+neonates O
+) O
+with O
+10 O
+attributable O
+to O
+HSV O
+disease O
+. O
+
+Conclusion O
+The O
+incidence B-EPI
+of O
+neonatal O
+HSV O
+disease O
+in O
+QLD O
+is O
+almost O
+3 O
+times O
+the O
+national O
+reported O
+incidence B-EPI
+. O
+
+Further O
+research O
+is O
+being O
+undertaken O
+to O
+explore O
+reasons O
+for O
+this O
+change O
+and O
+implications O
+for O
+practice O
+. O
+
+Xanthogranulomatous O
+cholecystitis O
+( O
+XGC O
+) O
+is O
+a O
+rare O
+form O
+of O
+cholecystitis O
+, O
+characterized O
+by O
+the O
+presence O
+of O
+xanthogranuloma O
+, O
+prominent O
+yellow O
+structures O
+within O
+the O
+gallbladder O
+wall O
+that O
+is O
+very O
+often O
+lithiasic O
+. O
+
+When O
+XGC O
+presents O
+in O
+its O
+pseudo O
+- O
+tumoral O
+form O
+with O
+occasional O
+adjacent O
+organ O
+involvement O
+, O
+it O
+can O
+mimic O
+gallbladder O
+carcinoma O
+( O
+GBC O
+) O
+. O
+
+The O
+etiopathogenesis O
+of O
+XGC O
+is O
+inflammatory O
+destruction O
+of O
+Rokitansky O
+- O
+Aschoff O
+sinuses O
+containing O
+biliary O
+and O
+cholesterol O
+pigments O
+within O
+the O
+gallbladder O
+wall O
+; O
+this O
+leads O
+to O
+a O
+florid O
+granulomatous O
+histiocytic O
+inflammatory O
+reaction O
+. O
+
+The O
+prevalence B-EPI
+ranges O
+from O
+1.3 O
+% O
+to I-STAT
+8.8 I-STAT
+% O
+of O
+all O
+cholecystectomies O
+and O
+varies O
+from O
+country O
+to O
+country O
+; O
+XGC O
+occurs B-EPI
+predominantly O
+in O
+patients O
+over O
+50 O
+years O
+of O
+age O
+, O
+and O
+is O
+equally O
+distributed O
+between O
+males B-SEX
+and O
+females B-SEX
+. O
+
+Its O
+association O
+with O
+GBC O
+remains O
+a O
+topic O
+of O
+debate O
+in O
+the O
+literature O
+( O
+between O
+0 I-STAT
+and I-STAT
+20 I-STAT
+% O
+) O
+. O
+
+Symptoms O
+are O
+non O
+- O
+specific O
+and O
+generally O
+similar O
+to O
+those O
+of O
+acute O
+or O
+chronic O
+cholecystitis O
+. O
+
+XGC O
+, O
+when O
+associated O
+with O
+altered O
+health O
+status O
+, O
+leads O
+to O
+the O
+suspicion O
+of O
+GBC O
+. O
+
+XGC O
+can O
+also O
+come O
+to O
+light O
+due O
+to O
+an O
+acute O
+complication O
+of O
+cholecystolithiasis O
+, O
+in O
+particular O
+, O
+gallstone O
+migration O
+. O
+
+Imaging O
+by O
+sonography O
+and O
+CT O
+scan O
+is O
+suggestive O
+, O
+but O
+magnetic O
+resonance O
+imaging O
+is O
+more O
+specific O
+. O
+
+In O
+difficult O
+cases O
+, O
+biopsy O
+may O
+be O
+necessary O
+to O
+eliminate O
+the O
+diagnosis O
+of O
+tumor O
+. O
+
+In O
+case O
+of O
+pre- O
+or O
+intra O
+- O
+operative O
+diagnostic O
+doubt O
+, O
+the O
+opinion O
+of O
+a O
+hepatobiliary O
+specialty O
+center O
+can O
+be O
+of O
+help O
+. O
+
+When O
+diagnosis O
+of O
+GBC O
+has O
+been O
+eliminated O
+, O
+laparoscopic O
+cholecystectomy O
+is O
+recommended O
+, O
+although O
+with O
+a O
+high O
+risk O
+of O
+conversion O
+to O
+laparotomy O
+and O
+complications O
+. O
+
+Background O
+and O
+Objectives O
+: O
+The O
+incidence B-EPI
+of O
+diverticulitis O
+is O
+increasing O
+in O
+western O
+countries O
+. O
+
+Complicated O
+diverticulitis O
+is O
+defined O
+as O
+diverticulitis O
+associated O
+with O
+localized O
+or O
+generalized O
+perforation O
+, O
+localized O
+or O
+distant O
+abscess O
+, O
+fistula O
+, O
+stricture O
+or O
+obstruction O
+. O
+
+Colonic O
+symptomatic O
+strictures O
+are O
+often O
+treated O
+with O
+segmental O
+colectomy O
+. O
+
+The O
+aim O
+of O
+our O
+study O
+is O
+to O
+report O
+our O
+experience O
+with O
+Self O
+Expandable O
+Metal O
+Stents O
+( O
+SEMS O
+) O
+placement O
+to O
+relieve O
+sigmoid O
+obstruction O
+secondary O
+to O
+diverticulitis O
+, O
+either O
+as O
+a O
+permanent O
+solution O
+or O
+as O
+a O
+bridge O
+to O
+elective O
+colectomy O
+. O
+
+Material O
+and O
+Methods O
+: O
+From O
+January B-DATE
+2016 I-DATE
+to I-DATE
+December I-DATE
+2018 I-DATE
+, O
+21 O
+patients O
+underwent O
+SEMS O
+placement O
+for O
+sigmoid O
+obstruction O
+secondary O
+to O
+diverticulitis O
+at O
+our O
+institution O
+. O
+
+In O
+four O
+patients O
+with O
+poor O
+general O
+conditions O
+, O
+SEMS O
+was O
+considered O
+the O
+definitive O
+form O
+of O
+treatment O
+. O
+
+In O
+17 O
+patients O
+, O
+the O
+stent O
+was O
+placed O
+as O
+bridge O
+to O
+elective O
+colectomy O
+. O
+
+Data O
+were O
+prospectively O
+collected O
+and O
+retrospectively O
+analyzed O
+. O
+
+Primary O
+outcomes O
+were O
+postoperative O
+mortality O
+and O
+morbidity O
+after O
+SEMS O
+and O
+subsequent O
+elective O
+colectomy O
+. O
+
+Results O
+: O
+There O
+was O
+no O
+mortality O
+or O
+major O
+morbidity O
+after O
+SEMS O
+placement O
+or O
+subsequent O
+elective O
+colectomy O
+. O
+
+No O
+stoma O
+was O
+performed O
+. O
+
+Conclusions O
+: O
+Placement O
+of O
+Colorectal O
+Self O
+Expandable O
+Stent O
+represents O
+a O
+useful O
+tool O
+to O
+relieve O
+obstruction O
+in O
+patients O
+with O
+left O
+- O
+sided O
+colonic O
+diverticulitis O
+. O
+
+SEMS O
+placement O
+makes O
+it O
+possible O
+to O
+transform O
+an O
+emergency O
+clinical O
+condition O
+into O
+an O
+elective O
+condition O
+, O
+giving O
+time O
+to O
+resolve O
+the O
+inflammation O
+and O
+the O
+infection O
+inevitably O
+associated O
+with O
+complicated O
+diverticulitis O
+. O
+
+Oculo O
+- O
+auriculo O
+- O
+vertebral O
+spectrum O
+is O
+a O
+complex O
+developmental O
+disorder O
+characterised O
+mainly O
+by O
+anomalies O
+of O
+the O
+ear O
+, O
+hemifacial O
+microsomia O
+, O
+epibulbar O
+dermoids O
+and O
+vertebral O
+anomalies O
+. O
+
+The O
+aetiology O
+is O
+largely O
+unknown O
+, O
+and O
+the O
+epidemiological O
+data O
+are O
+limited O
+and O
+inconsistent O
+. O
+
+We O
+present O
+the O
+largest O
+population O
+- O
+based O
+epidemiological O
+study O
+to O
+date O
+, O
+using O
+data O
+provided O
+by O
+the O
+large O
+network O
+of O
+congenital O
+anomalies O
+registries O
+in O
+Europe B-LOC
+. O
+
+The O
+study O
+population O
+included O
+infants O
+diagnosed O
+with O
+oculo O
+- O
+auriculo O
+- O
+vertebral O
+spectrum O
+during O
+the O
+1990 B-DATE
+- I-DATE
+2009 I-DATE
+period O
+from O
+34 O
+registries O
+active O
+in O
+16 O
+European B-LOC
+countries O
+. O
+
+Of O
+the O
+355 O
+infants O
+diagnosed O
+with O
+oculo O
+- O
+auriculo O
+- O
+vertebral O
+spectrum O
+, O
+there O
+were O
+95.8 O
+% O
+( O
+340/355 O
+) O
+live O
+born O
+, O
+0.8 O
+% O
+( O
+3/355 O
+) O
+fetal O
+deaths O
+, O
+3.4 O
+% O
+( O
+12/355 O
+) O
+terminations O
+of O
+pregnancy O
+for O
+fetal O
+anomaly O
+and O
+1.5 O
+% O
+( O
+5/340 O
+) O
+neonatal O
+deaths O
+. O
+
+In O
+18.9 O
+% O
+, O
+there O
+was O
+prenatal O
+detection O
+of O
+anomaly O
+/ O
+anomalies O
+associated O
+with O
+oculo O
+- O
+auriculo O
+- O
+vertebral O
+spectrum O
+, O
+69.7 O
+% O
+were O
+diagnosed O
+at O
+birth O
+, O
+3.9 O
+% O
+in O
+the O
+first O
+week O
+of O
+life O
+and O
+6.1 O
+% O
+within O
+1 O
+year O
+of O
+life O
+. O
+
+Microtia O
+( O
+88.8 O
+% O
+) O
+, O
+hemifacial O
+microsomia O
+( O
+49.0 O
+% O
+) O
+and O
+ear O
+tags O
+( O
+44.4 O
+% O
+) O
+were O
+the O
+most O
+frequent O
+anomalies O
+, O
+followed O
+by O
+atresia O
+/ O
+stenosis O
+of O
+external O
+auditory O
+canal O
+( O
+25.1 O
+% O
+) O
+, O
+diverse O
+vertebral O
+( O
+24.3 O
+% O
+) O
+and O
+eye O
+( O
+24.3 O
+% O
+) O
+anomalies O
+. O
+
+There O
+was O
+a O
+high O
+rate O
+( O
+69.5 O
+% O
+) O
+of O
+associated O
+anomalies O
+of O
+other O
+organs O
+/ O
+systems O
+. O
+
+The O
+most O
+common O
+were O
+congenital O
+heart O
+defects O
+present O
+in O
+27.8 O
+% O
+of O
+patients O
+. O
+
+The O
+prevalence B-EPI
+of O
+oculo O
+- O
+auriculo O
+- O
+vertebral O
+spectrum O
+, O
+defined O
+as O
+microtia O
+/ O
+ear O
+anomalies O
+and O
+at O
+least O
+one O
+major O
+characteristic O
+anomaly O
+, O
+was O
+3.8 B-STAT
+per I-STAT
+100,000 I-STAT
+births I-STAT
+. O
+
+Twinning O
+, O
+assisted O
+reproductive O
+techniques O
+and O
+maternal O
+pre O
+- O
+pregnancy O
+diabetes O
+were O
+confirmed O
+as O
+risk O
+factors O
+. O
+
+The O
+high O
+rate O
+of O
+different O
+associated O
+anomalies O
+points O
+to O
+the O
+need O
+of O
+performing O
+an O
+early O
+ultrasound O
+screening O
+in O
+all O
+infants O
+born O
+with O
+this O
+disorder O
+. O
+
+Background O
+21 O
+- O
+hydroxylase O
+deficiency O
+( O
+21OHD O
+) O
+is O
+an O
+autosomal O
+recessive O
+disorder O
+with O
+an O
+incidence B-EPI
+of O
+1:10,000 B-STAT
+- I-STAT
+1:20,000 I-STAT
+and O
+is O
+the O
+result O
+of O
+various O
+mutations O
+in O
+the O
+CYP21A2 O
+gene O
+. O
+
+21OHD O
+has O
+been O
+described O
+in O
+many O
+different O
+populations O
+, O
+but O
+it O
+has O
+not O
+been O
+studied O
+in O
+Roma B-ETHN
+individuals O
+so O
+far O
+. O
+
+The O
+aim O
+of O
+the O
+study O
+was O
+to O
+analyse O
+the O
+genotype O
+in O
+Roma B-ETHN
+patients O
+with O
+21OHD O
+and O
+the O
+prevalence B-EPI
+of O
+the O
+disease O
+in O
+the O
+Roma B-ETHN
+population O
+of O
+North B-LOC
+Macedonia I-LOC
+. O
+
+Methods O
+Molecular O
+analysis O
+of O
+the O
+nine O
+most O
+frequent O
+CYP21A2 O
+mutations O
+in O
+all O
+known O
+Roma B-ETHN
+patients O
+with O
+CAH O
+in O
+North B-LOC
+Macedonia I-LOC
+, O
+relatives O
+and O
+healthy O
+individuals O
+of O
+Roma B-ETHN
+ancestry O
+, O
+using O
+the O
+PCR O
+/ O
+ACRS O
+method O
+. O
+
+Results O
+Ten O
+Roma O
+patients O
+with O
+21OHD O
+were O
+identified O
+, O
+of O
+which O
+nine O
+had O
+the O
+salt O
+- O
+wasting O
+and O
+one O
+had O
+the O
+simple O
+virilizing O
+form O
+. O
+
+Calculated B-EPI
+incidence I-EPI
+of O
+21OHD O
+in O
+the O
+North B-ETHN
+Macedonian I-ETHN
+Roma I-ETHN
+population O
+was O
+1:3375 B-STAT
+. O
+
+Interestingly O
+, O
+9/10 O
+patients O
+( O
+90 O
+% O
+) O
+were O
+homozygous O
+for O
+the O
+In2 O
+G O
+splicing O
+mutation O
+( O
+293 O
+- O
+13A O
+/ O
+C O
+> O
+G O
+) O
+. O
+
+Standard O
+therapy O
+with O
+hydrocortisone O
+and O
+fludrocortisone O
+had O
+been O
+introduced O
+according O
+to O
+the O
+guidelines O
+. O
+
+In O
+16 O
+healthy O
+relatives O
+investigated O
+for O
+CYP21A2 O
+mutations O
+, O
+heterozygosity O
+for O
+the O
+In2 O
+G O
+mutation O
+was O
+detected O
+in O
+13/32 O
+( O
+40.6 O
+% O
+) O
+alleles O
+. O
+
+In O
+100 O
+healthy O
+Roma B-ETHN
+individuals O
+, O
+none O
+related O
+to O
+the O
+analysed O
+families O
+, O
+no O
+CYP21A2 O
+mutations O
+were O
+detected O
+. O
+
+Conclusion O
+The O
+Roma B-ETHN
+population O
+in O
+North B-LOC
+Macedonia I-LOC
+had O
+a O
+very O
+high O
+incidence B-EPI
+of O
+classic O
+21OHD O
+. O
+
+Almost O
+all O
+patients O
+had O
+the O
+severe O
+salt O
+- O
+wasting O
+form O
+and O
+the O
+In2G O
+/ O
+In2 O
+G O
+genotype O
+. O
+
+BACKGROUND O
+: O
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+assess O
+the O
+incidence B-EPI
+of O
+fractures O
+in O
+infancy O
+, O
+overall O
+and O
+by O
+type O
+of O
+fracture O
+, O
+its O
+association O
+with O
+accidents O
+, O
+metabolic O
+bone O
+disease O
+risk O
+factors O
+, O
+and O
+abuse O
+diagnosis O
+. O
+
+METHODS O
+: O
+The O
+design O
+was O
+a O
+population O
+- O
+based O
+register O
+study O
+in O
+Sweden B-LOC
+. O
+
+Participants O
+: O
+Children O
+born O
+1997 B-DATE
+- I-DATE
+2014 I-DATE
+, O
+0 O
+- O
+1 O
+years O
+of O
+age O
+diagnosed O
+with O
+fracture O
+- O
+diagnosis O
+according O
+to O
+International O
+Classification O
+of O
+Diseases O
+( O
+ICD10 O
+) O
+were O
+retrieved O
+from O
+the O
+National O
+Patient O
+Register O
+and O
+linked O
+to O
+the O
+Swedish B-ETHN
+Medical O
+Birth O
+Register O
+and O
+the O
+Death O
+Cause O
+Register O
+. O
+
+Main O
+outcome O
+measures O
+were O
+fractures O
+of O
+the O
+skull O
+, O
+long O
+bone O
+, O
+clavicle O
+and O
+ribs O
+, O
+categorized O
+by O
+age O
+( O
+younger O
+or O
+older O
+than O
+6 O
+months O
+) O
+, O
+and O
+accident O
+or O
+not O
+. O
+
+FINDINGS O
+: O
+The O
+incidence B-EPI
+of O
+fractures O
+during O
+infancy O
+was O
+251 B-STAT
+per I-STAT
+100000.0 I-STAT
+infants I-STAT
+( O
+n O
+= O
+4663 O
+) O
+. O
+
+Major O
+fracture O
+localisations O
+were O
+long O
+bone O
+( O
+44·9 O
+% O
+) O
+, O
+skull O
+( O
+31·7 O
+% O
+) O
+, O
+and O
+clavicle O
+( O
+18·6 O
+% O
+) O
+, O
+while O
+rib O
+fractures O
+were O
+few O
+( O
+1·4 O
+% O
+) O
+. O
+
+Fall O
+accidents O
+were O
+reported O
+among O
+71·4 O
+% O
+. O
+
+One O
+- O
+third O
+occurred O
+during O
+the O
+first O
+6 O
+months O
+. O
+
+Metabolic O
+bone O
+disease O
+risk O
+factors O
+, O
+such O
+as O
+maternal O
+obesity O
+, O
+preterm O
+birth O
+, O
+vitamin O
+D O
+deficiency O
+, O
+rickets O
+, O
+and O
+calcium O
+metabolic O
+disturbances O
+, O
+had O
+increased O
+odds O
+of O
+fractures O
+of O
+long O
+bones O
+and O
+ribs O
+in O
+early O
+infancy O
+( O
+0 O
+- O
+6 O
+months O
+): O
+birth O
+32 O
+- O
+36 O
+weeks O
+and O
+long O
+bone O
+fracture O
+[ O
+AOR O
+2·13 O
+( O
+95%CI O
+1·67 O
+- O
+2·93 O
+) O
+] O
+and O
+rib O
+fracture O
+[ O
+AOR O
+4·24 O
+( O
+95%CI O
+1·40 O
+- O
+12·8 O
+) O
+] O
+. O
+
+Diagnosis O
+of O
+vitamin O
+D O
+deficiency O
+/ O
+rickets O
+/ O
+disorders O
+of O
+calcium O
+metabolism O
+had O
+increased O
+odds O
+of O
+long O
+bone O
+fracture O
+[ O
+AOR O
+49·5 O
+( O
+95%CI O
+18·3 O
+- O
+134 O
+) O
+] O
+and O
+rib O
+fracture O
+[ O
+AOR O
+617 O
+( O
+95%CI O
+162 O
+- O
+2506 O
+) O
+] O
+. O
+
+Fractures O
+without O
+a O
+reported O
+accident O
+had O
+higher O
+odds O
+of O
+metabolic O
+risk O
+factors O
+than O
+those O
+with O
+reported O
+accidents O
+. O
+
+Abuse O
+diagnosis O
+was O
+registered O
+in O
+105 O
+infants O
+, O
+with O
+overrepresentation O
+of O
+preterm O
+births O
+, O
+multiple O
+births O
+and O
+small O
+- O
+for O
+- O
+gestational O
+age O
+. O
+
+INTERPRETATION O
+: O
+Metabolic O
+bone O
+disease O
+risk O
+factors O
+are O
+strongly O
+associated O
+with O
+fractures O
+of O
+long O
+bone O
+and O
+ribs O
+in O
+early O
+infancy O
+. O
+
+Fracture O
+cases O
+with O
+abuse O
+diagnosis O
+had O
+a O
+metabolic O
+bone O
+risk O
+factor O
+profile O
+. O
+
+End O
+- O
+stage O
+renal O
+disease O
+( O
+ESRD O
+) O
+is O
+associated O
+with O
+a O
+number O
+of O
+serious O
+complications O
+, O
+including O
+increased O
+cardiovascular O
+disease O
+, O
+anaemia O
+and O
+metabolic O
+bone O
+disease O
+. O
+
+Optic O
+atrophy O
+secondary O
+to O
+chronic O
+anaemia O
+in O
+ESRD O
+is O
+rare O
+. O
+
+We O
+report O
+a O
+case O
+of O
+bilateral O
+optic O
+atrophy O
+in O
+a O
+young O
+patient O
+with O
+chronic O
+anaemia O
+secondary O
+to O
+ESRD O
+. O
+
+A O
+23 O
+- O
+year O
+- O
+old O
+lady B-SEX
+with O
+ESRD O
+, O
+presented O
+with O
+progressive O
+blurring O
+of O
+vision O
+in O
+her O
+left O
+eye O
+for O
+a O
+period O
+of O
+six O
+months O
+. O
+
+Visual O
+acuity O
+in O
+the O
+left O
+eye O
+was O
+counting O
+finger O
+and O
+the O
+right O
+eye O
+was O
+6/6 O
+. O
+
+Left O
+optic O
+nerve O
+functions O
+were O
+significantly O
+reduced O
+. O
+
+Bilateral O
+anterior O
+segments O
+and O
+intraocular O
+pressure O
+were O
+normal O
+. O
+
+Funduscopy O
+showed O
+bilateral O
+pale O
+disc O
+with O
+arteriolar O
+attenuation O
+. O
+
+The O
+infective O
+, O
+autoimmune O
+and O
+demyelinating O
+screening O
+were O
+negative O
+. O
+
+Serial O
+full O
+blood O
+count O
+indicated O
+low O
+haemoglobin O
+and O
+haematocrit O
+value O
+. O
+
+The O
+full O
+blood O
+picture O
+revealed O
+normocytic O
+normochromic O
+anaemia O
+. O
+
+Neuroimaging O
+was O
+normal O
+. O
+
+The O
+patient O
+was O
+diagnosed O
+as O
+having O
+bilateral O
+optic O
+atrophy O
+secondary O
+to O
+chronic O
+anaemia O
+due O
+to O
+ESRD O
+. O
+
+Chronic O
+anaemia O
+is O
+a O
+potential O
+cause O
+of O
+optic O
+atrophy O
+in O
+a O
+young O
+patient O
+with O
+chronic O
+disease O
+. O
+
+Management O
+of O
+anaemia O
+in O
+such O
+cases O
+is O
+crucial O
+to O
+prevent O
+irreversible O
+complications O
+including O
+optic O
+atrophy O
+and O
+blindness O
+. O
+
+Pharmacological O
+, O
+technological O
+and O
+educational O
+approaches O
+have O
+advanced O
+the O
+treatment O
+of O
+Type O
+1 O
+diabetes O
+in O
+the O
+last O
+four O
+decades O
+and O
+yet O
+diabetic O
+ketoacidosis O
+( O
+DKA O
+) O
+continues O
+to O
+be O
+a O
+leading O
+cause O
+of O
+admission O
+in O
+Type O
+1 O
+diabetes O
+. O
+
+This O
+article O
+begins O
+by O
+reviewing O
+the O
+contemporary O
+epidemiological O
+evidence O
+in O
+DKA O
+. O
+
+It O
+highlights O
+a O
+rise O
+in O
+DKA O
+episodes O
+in O
+the O
+last O
+two O
+decades O
+, O
+with O
+DKA O
+continuing O
+to O
+be O
+the O
+leading O
+cause O
+of O
+death O
+in O
+young O
+people O
+with O
+Type O
+1 O
+diabetes O
+, O
+and O
+that O
+DKA O
+episodes O
+are O
+a O
+marker O
+for O
+subsequent O
+all O
+- O
+cause O
+mortality O
+. O
+
+It O
+also O
+summarizes O
+the O
+limited O
+evidence O
+base O
+for O
+DKA O
+prevention O
+and O
+associations O
+with O
+psychopathology O
+. O
+
+To O
+emphasize O
+the O
+importance O
+of O
+this O
+group O
+with O
+high O
+- O
+risk O
+Type O
+1 O
+diabetes O
+and O
+the O
+degree O
+to O
+which O
+they O
+have O
+been O
+overlooked O
+in O
+the O
+past O
+two O
+decades O
+, O
+the O
+article O
+summarizes O
+the O
+research O
+literature O
+of O
+recurrent O
+DKA O
+during O
+1976 B-DATE
+- I-DATE
+1991 I-DATE
+when O
+it O
+was O
+extensively O
+investigated O
+as O
+part O
+of O
+the O
+phenomenon O
+of O
+' O
+brittle O
+diabetes O
+' O
+. O
+
+This O
+period O
+saw O
+numerous O
+basic O
+science O
+studies O
+investigating O
+the O
+pathophysiology O
+of O
+recurrent O
+DKA O
+. O
+
+Subsequently O
+, O
+research O
+centres O
+published O
+their O
+experiences O
+of O
+brittle O
+diabetes O
+research O
+participants O
+manipulating O
+their O
+treatment O
+under O
+research O
+conditions O
+. O
+
+Unfortunately O
+, O
+the O
+driver O
+for O
+this O
+behaviour O
+and O
+whether O
+it O
+was O
+indicative O
+of O
+other O
+people O
+with O
+ketoacidosis O
+was O
+not O
+pursued O
+. O
+
+In O
+summary O
+, O
+we O
+suggest O
+there O
+has O
+been O
+a O
+stasis O
+in O
+the O
+approach O
+to O
+recurrent O
+DKA O
+prevention O
+, O
+which O
+is O
+likely O
+linked O
+to O
+historical O
+cases O
+of O
+mass O
+sabotage O
+of O
+brittle O
+diabetes O
+research O
+. O
+
+Further O
+investigation O
+is O
+required O
+to O
+clarify O
+possible O
+psychological O
+characteristics O
+that O
+increase O
+the O
+risk O
+of O
+DKA O
+and O
+thereby O
+targets O
+for O
+DKA O
+prevention O
+. O
+
+Importance O
+: O
+Congenital O
+retinal O
+macrovessel O
+( O
+CRM O
+) O
+is O
+a O
+rarely O
+reported O
+venous O
+malformation O
+of O
+the O
+retina O
+that O
+is O
+associated O
+with O
+venous O
+anomalies O
+of O
+the O
+brain O
+. O
+
+Objective O
+: O
+To O
+study O
+the O
+multimodal O
+imaging O
+findings O
+of O
+a O
+series O
+of O
+eyes O
+with O
+congenital O
+retinal O
+macrovessel O
+and O
+describe O
+the O
+systemic O
+associations O
+. O
+
+Design O
+, O
+Setting O
+, O
+and O
+Participants O
+: O
+In O
+this O
+cross O
+- O
+sectional O
+multicenter O
+study O
+, O
+medical O
+records O
+were O
+retrospectively O
+reviewed O
+from O
+7 O
+different O
+retina O
+clinics O
+worldwide B-LOC
+over O
+a O
+10 O
+- O
+year O
+period O
+( O
+2007 B-DATE
+- I-DATE
+2017 I-DATE
+) O
+. O
+
+Patients O
+with O
+CRM O
+, O
+defined O
+as O
+an O
+abnormal O
+, O
+large O
+, O
+macular O
+vessel O
+with O
+a O
+vascular O
+distribution O
+above O
+and O
+below O
+the O
+horizontal O
+raphe O
+, O
+were O
+identified O
+. O
+
+Data O
+were O
+analyzed O
+from O
+December B-DATE
+2016 I-DATE
+to I-DATE
+August I-DATE
+2017 I-DATE
+. O
+
+Main O
+Outcomes O
+and O
+Measures O
+: O
+Clinical O
+information O
+and O
+multimodal O
+retinal O
+imaging O
+findings O
+were O
+collected O
+and O
+studied O
+. O
+
+Pertinent O
+systemic O
+information O
+, O
+including O
+brain O
+magnetic O
+resonance O
+imaging O
+findings O
+, O
+was O
+also O
+noted O
+if O
+available O
+. O
+
+Results O
+: O
+Of O
+the O
+49 O
+included O
+patients O
+, O
+32 O
+( O
+65 O
+% O
+) O
+were O
+female B-SEX
+, O
+and O
+the O
+mean O
+( O
+SD O
+) O
+age O
+at O
+onset O
+was O
+44.0 O
+( O
+20.9 O
+) O
+years O
+. O
+
+A O
+total O
+of O
+49 O
+eyes O
+from O
+49 O
+patients O
+were O
+studied O
+. O
+
+Macrovessel O
+was O
+unilateral O
+in O
+all O
+patients O
+. O
+
+Color O
+fundus O
+photography O
+illustrated O
+a O
+large O
+aberrant O
+dilated O
+and O
+tortuous O
+retinal O
+vein O
+in O
+all O
+patients O
+. O
+
+Early O
+- O
+phase O
+frames O
+of O
+fluorescein O
+angiography O
+further O
+confirmed O
+the O
+venous O
+nature O
+of O
+the O
+macrovessel O
+in O
+40 O
+of O
+40 O
+eyes O
+. O
+
+Optical O
+coherence O
+tomography O
+angiography O
+, O
+available O
+in O
+17 O
+eyes O
+( O
+35 O
+% O
+) O
+, O
+displayed O
+microvascular O
+capillary O
+abnormalities O
+around O
+the O
+CRM O
+, O
+which O
+were O
+more O
+evident O
+in O
+the O
+deep O
+capillary O
+plexus O
+. O
+
+Of O
+the O
+49 O
+patients O
+with O
+CRM O
+, O
+39 O
+( O
+80 O
+% O
+) O
+did O
+not O
+illustrate O
+any O
+evidence O
+of O
+ophthalmic O
+complications O
+. O
+
+Ten O
+patients O
+( O
+20 O
+% O
+) O
+presented O
+with O
+retinal O
+complications O
+, O
+typically O
+an O
+incidental O
+association O
+with O
+CRM O
+. O
+
+Twelve O
+patients O
+( O
+24 O
+% O
+) O
+were O
+noted O
+to O
+have O
+venous O
+malformations O
+of O
+the O
+brain O
+with O
+associated O
+magnetic O
+resonance O
+imaging O
+. O
+
+Of O
+these O
+, O
+location O
+of O
+the O
+venous O
+anomaly O
+in O
+the O
+brain O
+was O
+ipsilateral O
+to O
+the O
+CRM O
+in O
+10 O
+patients O
+( O
+83 O
+% O
+) O
+and O
+contralateral O
+in O
+2 O
+patients O
+( O
+17 O
+% O
+) O
+, O
+mainly O
+located O
+in O
+the O
+frontal O
+lobe O
+in O
+9 O
+patients O
+( O
+75 O
+% O
+) O
+. O
+
+Conclusions O
+and O
+Relevance O
+: O
+Our O
+study O
+has O
+identified O
+an O
+association O
+between O
+macrovessels O
+in O
+the O
+retina O
+and O
+venous O
+anomalies O
+of O
+the O
+brain O
+( O
+24 O
+% O
+compared O
+with O
+0.2 O
+% O
+to O
+6.0 O
+% O
+in O
+the O
+normal O
+population O
+) O
+. O
+
+Thus O
+, O
+we O
+recommend O
+new O
+guidelines O
+for O
+the O
+systemic O
+workup O
+of O
+patients O
+with O
+CRM O
+to O
+include O
+brain O
+magnetic O
+resonance O
+imaging O
+with O
+contrast O
+. O
+
+These O
+lesions O
+may O
+be O
+more O
+accurately O
+referred O
+to O
+as O
+retinal O
+venous O
+malformations O
+, O
+which O
+may O
+raise O
+awareness O
+regarding O
+potential O
+cerebral O
+associations O
+. O
+
+Background O
+Sleep O
+disorders O
+are O
+common O
+in O
+people O
+with O
+intellectual O
+disability O
+( O
+ID O
+) O
+and O
+autism O
+, O
+with O
+growing O
+evidence O
+of O
+diverse O
+sleep O
+profiles O
+across O
+ID O
+associated O
+genetic O
+syndromes O
+. O
+
+Documenting O
+the O
+prevalence B-EPI
+and O
+profile O
+of O
+specific O
+sleep O
+disorders O
+in O
+syndromes O
+will O
+quantify O
+syndrome O
+- O
+driven O
+' O
+risk O
+' O
+, O
+inform O
+prognosis O
+and O
+enhance O
+understanding O
+of O
+aetiology O
+of O
+sleep O
+disorders O
+. O
+
+Method O
+Following O
+PRISMA O
+guidelines O
+for O
+meta O
+- O
+analysis O
+, O
+we O
+searched O
+Ovid O
+PsycINFO O
+, O
+Ovid O
+MEDLINE O
+, O
+Ovid O
+Embase O
+, O
+Web O
+of O
+Science O
+and O
+PubMed O
+Central O
+with O
+use O
+of O
+syndrome O
+- O
+specific O
+keywords O
+and O
+60 O
+sleep O
+- O
+related O
+search O
+terms O
+. O
+
+We O
+screened O
+and O
+extracted O
+papers O
+that O
+reported O
+sleep O
+disorder O
+prevalence B-EPI
+data O
+for O
+five O
+or O
+more O
+individuals O
+within O
+a O
+genetic O
+syndrome O
+, O
+and O
+applied O
+quality O
+criteria O
+to O
+produce O
+a O
+quality O
+- O
+effects O
+prevalence B-EPI
+model O
+of O
+six O
+types O
+of O
+sleep O
+disorder O
+across O
+nineteen O
+syndromes O
+. O
+
+Relative O
+risk O
+estimates O
+were O
+calculated O
+for O
+the O
+prevalence B-EPI
+of O
+each O
+sleep O
+disorder O
+in O
+each O
+syndrome O
+. O
+
+Results O
+Two O
+hundred O
+and O
+seventy O
+three O
+papers O
+were O
+identified O
+, O
+generating O
+463 O
+prevalence B-EPI
+estimates I-EPI
+for O
+Angelman O
+, O
+CHARGE O
+, O
+Cornelia O
+de O
+Lange O
+, O
+Down O
+, O
+fragile O
+X O
+, O
+Prader O
+- O
+Willi O
+, O
+Rett O
+, O
+Smith O
+- O
+Magenis O
+and O
+Williams O
+syndromes O
+, O
+mucopolysaccharidoses O
+( O
+MPS O
+disorders O
+) O
+, O
+neurofibromatosis O
+and O
+tuberous O
+sclerosis O
+complex O
+. O
+
+Prevalence B-EPI
+estimates I-EPI
+were O
+higher O
+in O
+genetic O
+syndromes O
+than O
+published O
+equivalents O
+for O
+typically O
+developing O
+individuals O
+, O
+with O
+few O
+exceptions O
+. O
+
+Between O
+- O
+syndrome O
+differences O
+for O
+some O
+disorders O
+were O
+evident O
+; O
+sleep O
+- O
+disordered O
+breathing O
+was O
+most O
+prevalent B-EPI
+in O
+MPS O
+disorders O
+( O
+72 O
+- O
+77 O
+% O
+) O
+, O
+while O
+excessive O
+daytime O
+sleepiness O
+was O
+highest O
+in O
+Smith O
+- O
+Magenis O
+syndrome O
+( O
+60 O
+% O
+) O
+. O
+
+Conversely O
+, O
+insomnia O
+, O
+which O
+was O
+reported O
+at O
+a O
+higher O
+rate O
+than O
+TD O
+estimates O
+in O
+all O
+syndromes O
+except O
+fragile O
+X O
+, O
+was O
+not O
+associated O
+with O
+specific O
+genetic O
+risk O
+. O
+
+This O
+suggests O
+insomnia O
+could O
+emerge O
+because O
+of O
+the O
+individual O
+'s O
+environment O
+or O
+associated O
+developmental O
+delay O
+, O
+rather O
+than O
+any O
+specific O
+genetic O
+syndromes O
+. O
+
+Limitations O
+Due O
+to O
+the O
+broad O
+scope O
+of O
+the O
+meta O
+- O
+analysis O
+, O
+only O
+syndromes O
+previously O
+identified O
+as O
+reporting O
+preliminary O
+sleep O
+research O
+were O
+included O
+. O
+
+Other O
+syndromes O
+may O
+also O
+experience O
+elevated O
+prevalence B-EPI
+rates I-EPI
+of O
+specific O
+types O
+of O
+sleep O
+disorder O
+. O
+
+Only O
+English O
+language O
+papers O
+were O
+included O
+. O
+
+Conclusions O
+Differing O
+prevalence B-EPI
+rates I-EPI
+between O
+types O
+of O
+sleep O
+disorder O
+suggest O
+differing O
+causal O
+mechanisms O
+, O
+such O
+as O
+cranio O
+- O
+facial O
+morphology O
+in O
+Down O
+and O
+Prader O
+- O
+Willi O
+syndromes O
+and O
+the O
+build O
+- O
+up O
+of O
+mucopolysaccharides O
+in O
+MPS O
+disorders O
+. O
+
+Priorities O
+for O
+clinical O
+assessment O
+and O
+intervention O
+for O
+sleep O
+disorders O
+are O
+discussed O
+. O
+
+Maternal O
+hypertensive O
+disorders O
+during O
+pregnancy O
+( O
+HDP O
+) O
+have O
+been O
+associated O
+with O
+neuropsychiatric O
+problems O
+in O
+offspring O
+. O
+
+We O
+aim O
+to O
+investigate O
+the O
+associations O
+between O
+specific O
+types O
+of O
+maternal O
+HDP O
+and O
+offspring O
+neurodevelopmental O
+disorders O
+and O
+further O
+examine O
+whether O
+the O
+timing O
+of O
+onset O
+and O
+severity O
+of O
+HDP O
+would O
+affect O
+these O
+associations O
+. O
+
+The O
+study O
+population O
+consisted O
+of O
+4,489,044 O
+live O
+- O
+born O
+singletons O
+in O
+Denmark B-LOC
+during O
+1978 B-DATE
+- I-DATE
+2012 I-DATE
+and O
+Sweden B-LOC
+during O
+1987 B-DATE
+- I-DATE
+2010 I-DATE
+. O
+
+Maternal O
+HDP O
+was O
+categorized O
+into O
+chronic O
+hypertension O
+, O
+gestational O
+hypertension O
+, O
+and O
+pre O
+- O
+eclampsia O
+; O
+pre O
+- O
+eclampsia O
+was O
+further O
+stratified O
+according O
+to O
+timing O
+( O
+early O
+- O
+onset O
+, O
+late O
+- O
+onset O
+) O
+, O
+or O
+severity O
+( O
+moderate O
+, O
+severe O
+) O
+of O
+the O
+disease O
+. O
+
+Neurodevelopmental O
+disorders O
+, O
+including O
+attention O
+- O
+deficit O
+/ O
+hyperactivity O
+disorder O
+( O
+ADHD O
+) O
+, O
+autism O
+spectrum O
+disorder O
+( O
+ASD O
+) O
+, O
+and O
+intellectual O
+disability O
+( O
+ID O
+) O
+, O
+were O
+defined O
+by O
+ICD O
+- O
+coded O
+register O
+diagnosis O
+. O
+
+Cox O
+regression O
+was O
+used O
+to O
+calculate O
+hazard O
+ratios O
+( O
+HR O
+) O
+while O
+adjusting O
+for O
+potential O
+confounders O
+, O
+and O
+sibling O
+analyses O
+assessed O
+the O
+influence O
+of O
+unmeasured O
+shared O
+familial O
+factors O
+. O
+
+Maternal O
+HDP O
+was O
+associated O
+with O
+increased O
+risks O
+of O
+ADHD O
+( O
+HR O
+, O
+1.24 O
+; O
+95 O
+% O
+confidence O
+interval O
+[ O
+CI O
+] O
+, O
+1.20 O
+- O
+1.28 O
+) O
+, O
+ASD O
+( O
+1.29 O
+[ O
+1.24 O
+- O
+1.34 O
+] O
+) O
+, O
+and O
+ID O
+( O
+1.58 O
+[ O
+1.50 O
+- O
+1.66 O
+] O
+) O
+in O
+offspring O
+, O
+respectively O
+, O
+which O
+was O
+mostly O
+driven O
+by O
+pre O
+- O
+eclampsia O
+. O
+
+The O
+strongest O
+associations O
+were O
+observed O
+for O
+early O
+- O
+onset O
+and O
+severe O
+pre O
+- O
+eclampsia O
+, O
+and O
+the O
+corresponding O
+HRs O
+for O
+ADHD O
+, O
+ASD O
+and O
+ID O
+were O
+1.93 O
+[ O
+1.73 O
+- O
+2.16 O
+] O
+, O
+1.86 O
+[ O
+1.61 O
+- O
+2.15 O
+] O
+, O
+and O
+3.99 O
+[ O
+3.42 O
+- O
+4.65 O
+] O
+, O
+respectively O
+. O
+
+The O
+results O
+were O
+similar O
+in O
+the O
+sibling O
+analyses O
+. O
+
+The O
+associations O
+between O
+maternal O
+HDP O
+and O
+offspring O
+neurodevelopmental O
+disorders O
+were O
+consistent O
+across O
+the O
+subgroups O
+of O
+sex O
+, O
+preterm O
+status O
+, O
+parity O
+, O
+maternal O
+age O
+and O
+psychiatric O
+disorders O
+. O
+
+Maternal O
+HDP O
+, O
+especially O
+early O
+- O
+onset O
+pre O
+- O
+eclampsia O
+, O
+are O
+associated O
+with O
+increased O
+risks O
+of O
+ADHD O
+, O
+ASD O
+, O
+and O
+ID O
+in O
+particular O
+, O
+independent O
+of O
+shared O
+familial O
+factors O
+. O
+
+Central O
+hypothyroidism O
+( O
+CH O
+) O
+occurs B-EPI
+approximately B-STAT
+in O
+1:50,000 I-STAT
+, O
+and O
+therefore O
+is O
+expected O
+to O
+be O
+one O
+thousand O
+times O
+rarer O
+compared O
+with O
+primary O
+hypothyroidism O
+. O
+
+Despite O
+its O
+rarity O
+in O
+the O
+general O
+population O
+, O
+it O
+is O
+much O
+more O
+common O
+in O
+certain O
+disorders O
+, O
+in O
+which O
+it O
+is O
+frequently O
+associated O
+with O
+other O
+pituitary O
+hormone O
+deficiencies O
+. O
+
+The O
+aim O
+of O
+this O
+paper O
+is O
+to O
+provide O
+an O
+updated O
+review O
+on O
+the O
+frequency B-EPI
+of O
+congenital O
+CH O
+, O
+which O
+is O
+< B-STAT
+1:50,000 I-STAT
+, O
+and O
+on O
+its O
+etiology O
+, O
+disregarding O
+CH O
+caused O
+by O
+other O
+genetic O
+defects O
+, O
+such O
+as O
+mutations O
+of O
+transcription O
+factors O
+involved O
+in O
+pituitary O
+organogenesis O
+or O
+mutations O
+of O
+the O
+genes O
+encoding O
+TRH O
+or O
+TRH O
+receptor O
+. O
+
+Aims O
+Coeliac O
+disease O
+( O
+CD O
+) O
+is O
+an O
+autoimmune O
+disorder O
+with O
+a O
+prevalence B-EPI
+≤2 B-STAT
+% I-STAT
+that O
+causes O
+an O
+immune O
+reaction O
+to O
+gluten O
+. O
+
+Growth O
+retardation O
+( O
+GR O
+) O
+generally O
+accompanies O
+CD O
+due O
+to O
+gastrointestinal O
+complications O
+and O
+should O
+be O
+treated O
+as O
+early O
+as O
+possible O
+along O
+with O
+initiation O
+of O
+a O
+gluten O
+- O
+free O
+diet O
+. O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+determine O
+the O
+indicators O
+of O
+GR O
+in O
+patients O
+with O
+CD O
+. O
+
+Methods O
+This O
+single O
+- O
+centre O
+retrospective O
+study O
+included O
+paediatric O
+outpatients O
+with O
+CD O
+. O
+
+All O
+patients O
+were O
+diagnosed O
+with O
+CD O
+via O
+serological O
+analysis O
+and O
+upper O
+gastrointestinal O
+endoscopy O
+if O
+necessary O
+. O
+
+Patient O
+records O
+were O
+obtained O
+from O
+Adana B-LOC
+City O
+Training O
+and O
+Research O
+Hospital O
+. O
+
+Patients O
+that O
+were O
+diagnosed O
+with O
+GR O
+accompanying O
+CD O
+were O
+given O
+oral O
+nutritional O
+supplements O
+and O
+followed O
+- O
+up O
+every O
+3 O
+- O
+6 O
+months O
+. O
+
+Statistical O
+relationships O
+between O
+demographics O
+, O
+and O
+anthropometric O
+measurements O
+, O
+duration O
+of O
+breastfeeding O
+, O
+gluten O
+contact O
+time O
+, O
+diet O
+duration O
+, O
+presenting O
+complaints O
+and O
+serological O
+findings O
+were O
+evaluated O
+. O
+
+Results O
+This O
+study O
+included O
+169 O
+paediatric O
+outpatients O
+between O
+ages O
+1 O
+and O
+18 O
+. O
+
+Longer O
+symptom O
+duration O
+and O
+shorter O
+breastfeeding O
+duration O
+were O
+significantly O
+correlated O
+with O
+GR O
+accompanying O
+CD O
+( O
+P O
+= O
+0.007 O
+and O
+P O
+= O
+0.029 O
+, O
+respectively O
+) O
+. O
+
+Vomiting O
+was O
+the O
+only O
+symptom O
+that O
+was O
+correlated O
+with O
+the O
+presence O
+of O
+GR O
+( O
+P O
+= O
+0.010 O
+) O
+. O
+
+Helicobacter O
+pylori O
+infection O
+was O
+not O
+correlated O
+with O
+the O
+presence O
+of O
+GR O
+( O
+P O
+= O
+0.277 O
+) O
+. O
+
+Conclusions O
+GR O
+should O
+be O
+treated O
+as O
+early O
+as O
+possible O
+to O
+reduce O
+the O
+severity O
+of O
+CD O
+and O
+a O
+6 O
+months O
+sole O
+breastfeeding O
+followed O
+by O
+solid O
+foods O
+accompanied O
+by O
+breastfeeding O
+for O
+2 O
+years O
+is O
+crucial O
+for O
+preventing O
+GR O
+. O
+
+Moreover O
+, O
+vomiting O
+as O
+a O
+presenting O
+complaint O
+in O
+patients O
+with O
+CD O
+might O
+be O
+indicative O
+of O
+the O
+presence O
+of O
+GR O
+. O
+
+Frailty O
+is O
+common O
+in O
+older O
+hospitalised O
+patients O
+and O
+may O
+be O
+associated O
+with O
+micronutrient O
+malnutrition O
+. O
+
+Only O
+limited O
+studies O
+have O
+explored O
+the O
+relationship O
+between O
+frailty O
+and O
+vitamin O
+C O
+deficiency O
+. O
+
+This O
+study O
+investigated O
+the O
+prevalence B-EPI
+of O
+vitamin O
+C O
+deficiency O
+and O
+its O
+association O
+with O
+frailty O
+severity O
+in O
+patients O
+≥75 O
+years O
+admitted O
+under O
+a O
+geriatric O
+unit O
+. O
+
+Patients O
+( O
+n O
+= O
+160 O
+) O
+with O
+a O
+mean O
+age O
+of O
+84.4 O
+± O
+6.4 O
+years O
+were O
+recruited O
+and O
+underwent O
+frailty O
+assessment O
+by O
+use O
+of O
+the O
+Edmonton O
+Frail O
+Scale O
+( O
+EFS O
+) O
+. O
+
+Patients O
+with O
+an O
+EFS O
+score O
+< O
+10 O
+were O
+classified O
+as O
+non O
+- O
+frail O
+/ O
+vulnerable O
+/ O
+mildly O
+frail O
+and O
+those O
+with O
+≥10 O
+as O
+moderate O
+- O
+severely O
+frail O
+. O
+
+Patients O
+with O
+vitamin O
+C O
+levels O
+between O
+11 O
+- O
+28 O
+μmol O
+/ O
+L O
+were O
+classified O
+as O
+vitamin O
+C O
+depleted O
+while O
+those O
+with O
+levels O
+< O
+11 O
+μmol O
+/ O
+L O
+were O
+classified O
+as O
+vitamin O
+C O
+deficient O
+. O
+
+A O
+multivariate O
+logistic O
+regression O
+model O
+determined O
+the O
+relationship O
+between O
+vitamin O
+C O
+deficiency O
+and O
+frailty O
+severity O
+after O
+adjustment O
+for O
+various O
+co O
+- O
+variates O
+. O
+
+Fifty O
+- O
+seven O
+( O
+35.6 O
+% O
+) O
+patients O
+were O
+vitamin O
+C O
+depleted O
+, O
+while O
+42 O
+( O
+26.3 O
+% O
+) O
+had O
+vitamin O
+C O
+deficiency O
+. O
+
+Vitamin O
+C O
+levels O
+were O
+significantly O
+lower O
+among O
+patients O
+who O
+were O
+moderate O
+- O
+severely O
+frail O
+when O
+compared O
+to O
+those O
+who O
+were O
+non O
+- O
+frail O
+/ O
+vulnerable O
+/ O
+mildly O
+frail O
+( O
+p O
+< O
+0.05 O
+) O
+. O
+
+After O
+adjusted O
+analysis O
+, O
+vitamin O
+C O
+deficiency O
+was O
+4.3 O
+- O
+fold O
+more O
+likely O
+to O
+be O
+associated O
+with O
+moderate O
+- O
+severe O
+frailty O
+( O
+aOR O
+4.30 O
+, O
+95 O
+% O
+CI O
+1.33 O
+- O
+13.86 O
+, O
+p O
+= O
+0.015 O
+) O
+. O
+
+Vitamin O
+C O
+deficiency O
+is O
+common O
+and O
+is O
+associated O
+with O
+a O
+greater O
+severity O
+of O
+frailty O
+in O
+older O
+hospitalised O
+patients O
+. O
+
+Ever O
+since O
+SARS O
+- O
+CoV-2 O
+began O
+infecting O
+people O
+by O
+the O
+end O
+of O
+2019 B-DATE
+, O
+of O
+whom O
+some O
+developed O
+severe O
+pneumonia O
+( O
+about O
+5 O
+% O
+) O
+, O
+which O
+could O
+be O
+fatal O
+( O
+case O
+fatality O
+~3.5 O
+% O
+) O
+, O
+the O
+extent O
+and O
+speed O
+of O
+the O
+COVID-19 O
+outbreak O
+has O
+been O
+phenomenal O
+. O
+
+Within O
+2.5 O
+months O
+( O
+by O
+March I-DATE
+18 I-DATE
+, I-DATE
+2020 I-DATE
+) O
+over O
+191,127 O
+COVID-19 O
+patients O
+have O
+been O
+identified O
+in O
+161 O
+countries O
+. O
+
+By O
+then O
+, O
+over O
+700 O
+pediatric O
+patients O
+were O
+confirmed O
+to O
+have O
+COVID-19 O
+in O
+China B-LOC
+, O
+with O
+only O
+about O
+58 O
+diagnosed O
+elsewhere O
+. O
+
+By O
+now O
+, O
+there O
+are O
+thousands O
+of O
+children O
+and O
+adolescents O
+infected O
+. O
+
+Chinese B-ETHN
+pediatricians O
+would O
+like O
+to O
+share O
+their O
+experience O
+on O
+how O
+these O
+patients O
+were O
+managed O
+in O
+China B-LOC
+and O
+the O
+key O
+recommendations O
+that O
+had O
+guided O
+them O
+in O
+meeting O
+the O
+evolving O
+challenges O
+. O
+
+A O
+group O
+of O
+experts O
+were O
+summoned O
+by O
+the O
+Chinese B-ETHN
+Pediatric O
+Society O
+and O
+Editorial O
+Board O
+of O
+Chinese B-ETHN
+Journal O
+of O
+Pediatrics O
+to O
+extract O
+informative O
+data O
+from O
+a O
+survey O
+on O
+confirmed O
+COVID-19 O
+pediatric O
+patients O
+in O
+China B-LOC
+. O
+
+Consensus O
+on O
+diagnosis O
+, O
+management O
+, O
+and O
+prevention O
+of O
+pediatric O
+COVID-19 O
+were O
+drawn O
+up O
+based O
+on O
+the O
+analysis O
+of O
+such O
+data O
+plus O
+insights O
+gained O
+from O
+the O
+past O
+SARS O
+and O
+MERS O
+coronavirus O
+outbreaks O
+. O
+
+Relevant O
+cumulating O
+experiences O
+from O
+physicians O
+managing O
+adult O
+patients O
+, O
+expedited O
+reports O
+on O
+clinical O
+and O
+scientific O
+COVID-19 O
+and O
+SARS O
+- O
+CoV-2 O
+data O
+, O
+and O
+the O
+National O
+Health O
+Committee O
+guidelines O
+on O
+COVID-19 O
+management O
+were O
+integrated O
+into O
+this O
+proposal O
+. O
+
+Rationale O
+Women B-SEX
+with O
+congenital O
+adrenal O
+hyperplasia O
+( O
+CAH O
+) O
+can O
+suffer O
+from O
+impaired O
+fertility O
+rates O
+as O
+a O
+result O
+of O
+increased O
+androgen O
+secretion O
+or O
+impaired O
+sex O
+steroid O
+production O
+. O
+
+CAH O
+patients O
+have O
+lower O
+pregnancy O
+rate O
+compared O
+to O
+normal O
+women B-SEX
+. O
+
+Only O
+a O
+few O
+cases O
+with O
+successful O
+pregnancy O
+have O
+been O
+reported O
+in O
+the O
+literature O
+. O
+
+This O
+report O
+described O
+a O
+case O
+of O
+CAH O
+with O
+successful O
+pregnancy O
+and O
+live O
+birth O
+. O
+
+Patient O
+concerns O
+A O
+23 O
+- O
+year O
+- O
+old O
+woman B-SEX
+visited O
+our O
+endocrinology O
+department O
+for O
+clitoral O
+hypertrophy O
+and O
+primary O
+amenorrhea O
+. O
+
+Diagnoses O
+The O
+patient O
+was O
+diagnosed O
+as O
+CAH O
+. O
+
+Intervention O
+Prednisone O
+was O
+initially O
+started O
+to O
+improve O
+the O
+patient O
+'s O
+symptoms O
+. O
+
+Then O
+she O
+underwent O
+clitoral O
+resection O
+and O
+vaginoplasty O
+several O
+months O
+later O
+. O
+
+She O
+continuously O
+took O
+the O
+prednisolone O
+after O
+the O
+operation O
+and O
+had O
+been O
+undergoing O
+regular O
+checkups O
+. O
+
+Outcomes O
+She O
+was O
+pregnant O
+spontaneously O
+without O
+assisted O
+reproductive O
+technology O
+and O
+had O
+a O
+successful O
+live O
+birth O
+. O
+
+Her O
+baby O
+had O
+shown O
+normal O
+external O
+genitalia O
+with O
+normal O
+karyotype O
+and O
+normal O
+development O
+up O
+to O
+6 O
+years O
+of O
+age O
+. O
+
+Lessons O
+Some O
+mild O
+CAH O
+patients O
+with O
+certain O
+types O
+can O
+achieved O
+successful O
+pregnancy O
+without O
+any O
+assisted O
+reproductive O
+technology O
+after O
+treatment O
+with O
+steroid O
+. O
+
+The O
+pregnancy O
+rate O
+among O
+CAH O
+women B-SEX
+who O
+wish O
+to O
+conceive O
+may O
+be O
+much O
+more O
+optimistic O
+than O
+previous O
+researches O
+. O
+
+Background O
+/ O
+aim O
+This O
+study O
+analysed O
+the O
+prevalence B-EPI
+of O
+the O
+characteristics O
+evaluated O
+in O
+dermatoscopy O
+for O
+melanocytic O
+infiltrations O
+of O
+the O
+conjunctiva O
+with O
+various O
+degrees O
+of O
+malignancy O
+. O
+
+Patients O
+and O
+methods O
+A O
+total O
+of O
+160 O
+conjunctival O
+pigmented O
+lesions O
+were O
+studied O
+. O
+
+Each O
+lesion O
+was O
+scored O
+using O
+dermatoscopic O
+patterns O
+and O
+the O
+characteristics O
+of O
+malignancy O
+described O
+by O
+Kittler O
+. O
+
+Also O
+, O
+the O
+Authors O
+' O
+own O
+clues O
+were O
+added O
+to O
+the O
+evaluation O
+. O
+
+Results O
+In O
+melanomas O
+, O
+the O
+following O
+characteristics O
+were O
+identified O
+: O
+asymmetry O
+of O
+the O
+pattern O
+and O
+colour O
+, O
+larger O
+average O
+number O
+of O
+colours O
+, O
+the O
+presence O
+of O
+grey O
+colour O
+, O
+structureless O
+area O
+, O
+polymorphic O
+vessels O
+and O
+feeder O
+vessels O
+. O
+
+A O
+pattern O
+of O
+black O
+dots O
+and O
+a O
+black O
+colour O
+was O
+typical O
+of O
+malignant O
+lesions O
+and O
+pre O
+- O
+cancerous O
+( O
+premalignant O
+) O
+lesions O
+- O
+primary O
+acquired O
+melanosis O
+( O
+PAM O
+) O
+with O
+atypia O
+. O
+
+Cysts O
+were O
+observed O
+only O
+in O
+the O
+group O
+of O
+naevi O
+. O
+
+Conclusion O
+The O
+patterns O
+evaluated O
+with O
+dermatoscopy O
+are O
+present O
+in O
+pigmented O
+lesions O
+of O
+the O
+conjunctiva O
+. O
+
+There O
+are O
+, O
+however O
+, O
+some O
+characteristics O
+which O
+allow O
+differentiation O
+between O
+melanoma O
+and O
+pigmented O
+naevus O
+and O
+melanosis O
+and O
+also O
+between O
+PAM O
+. O
+